U.S. patent application number 10/020780 was filed with the patent office on 2002-07-18 for guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists.
Invention is credited to Ares, Jeffrey Joseph, Bogdan, Sophie Eva, Cupps, Thomas Lee, Henry, Raymond Todd, Seibel, William Lee, Sheldon, Russell James.
Application Number | 20020095039 10/020780 |
Document ID | / |
Family ID | 23195410 |
Filed Date | 2002-07-18 |
United States Patent
Application |
20020095039 |
Kind Code |
A1 |
Cupps, Thomas Lee ; et
al. |
July 18, 2002 |
Guanidinylamino heterocycle compounds useful as alpha-2
adrenoceptor agonists
Abstract
This invention involves compounds having the following
structure: 1 as described in the Claims; and enantiomers, optical
isomers, stereoisomers, diastereomers, tautomers, addition salts,
biohydrolyzable amides and esters thereof, as well as
pharmaceutical compositions comprising such novel compounds. The
invention also relates to the use of such compounds for preventing
or treating disorders modulated by alpha-2 adrenoceptors.
Inventors: |
Cupps, Thomas Lee; (Norwich,
NY) ; Bogdan, Sophie Eva; (Maineville, OH) ;
Henry, Raymond Todd; (Pleasant Plain, OH) ; Sheldon,
Russell James; (Fairfield, OH) ; Seibel, William
Lee; (Hamilton, OH) ; Ares, Jeffrey Joseph;
(Hamilton, OH) |
Correspondence
Address: |
DAVID V. UPITE
THE PROCTER & GAMBLE COMPANY
HEALTH CARE RESEARCH CENTER
8700 MASON-MONTGOMERY ROAD
MASON
OH
45040
US
|
Family ID: |
23195410 |
Appl. No.: |
10/020780 |
Filed: |
December 14, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10020780 |
Dec 14, 2001 |
|
|
|
09919053 |
Jul 31, 2001 |
|
|
|
09919053 |
Jul 31, 2001 |
|
|
|
09665361 |
Sep 19, 2000 |
|
|
|
09665361 |
Sep 19, 2000 |
|
|
|
09308790 |
Aug 9, 1999 |
|
|
|
60031833 |
Nov 25, 1996 |
|
|
|
60031756 |
Nov 25, 1996 |
|
|
|
Current U.S.
Class: |
546/156 ;
544/353; 546/159; 548/152; 548/162; 548/167; 548/217; 548/306.4;
548/307.4 |
Current CPC
Class: |
C07D 235/06 20130101;
A61K 31/47 20130101; C07D 215/38 20130101; C07D 417/12 20130101;
C07D 215/06 20130101; C07D 215/16 20130101; C07D 277/62 20130101;
C07D 215/40 20130101 |
Class at
Publication: |
546/156 ;
546/159; 548/152; 548/162; 548/167; 548/217; 548/306.4; 548/307.4;
544/353 |
International
Class: |
C07D 277/60; C07D
263/52; C07D 235/26; C07D 235/30; C07D 241/40; C07D 215/38 |
Claims
What is claimed is:
1. A compound of formula; 13wherein; a) R.sub.1 is hydrogen; or
alkyl or nil; where R.sub.1 is nil, bond (a) is a double bond; b) D
is CR.sub.2 where R.sub.2 is selected from hydrogen; unsubstituted
C.sub.1-C.sub.3 alkanyl; amino, hydroxy, mercapto; C.sub.1-C.sub.3
alkylthio or alkoxy; C.sub.1-C.sub.3 alkylamino or C.sub.1-C.sub.3
dialkylamino and halo; or when B is CR.sub.3, D may be N; c) B is
NR.sub.9, CR.sub.3.dbd.CR.sub.8, CR.sub.3.dbd.N, CR.sub.3, S, O, SO
or SO.sub.2; wherein R.sub.9 is selected from hydrogen; and
unsubstituted C.sub.1-C.sub.3 alkanyl, alkenyl or alkynyl;
cycloalkanyl, cycloalkenyl; and wherein R.sub.3 and R.sub.8 are
each independently selected from hydrogen; unsubstituted
C.sub.1-C.sub.3 alkanyl, alkenyl or alkynyl; cycloalkanyl,
cycloalkenyl; unsubstituted C.sub.1-C.sub.3 alkylthio or alkoxy;
hydroxy; thio; nitro; cyano; amino; C.sub.1 -C.sub.3 alkylamino or
C.sub.1-C.sub.3 dialkylamino and halo; d) R.sub.4, R.sub.5 and
R.sub.6 are each independently selected from hydrogen;
unsubstituted C.sub.1-C.sub.3 alkanyl, alkenyl or alkynyl;
cycloalkanyl, cycloalkenyl; unsubstituted C.sub.1-C.sub.3 alkylthio
or alkoxy; hydroxy; thio; nitro; cyano; amino; C.sub.1-C.sub.3
alkylamino or C.sub.1-C.sub.3 dialkylamino; halo; and
NH--NH--C(.dbd.NR.sub.10)NHR.sub.- 11 (guanidinylamino); wherein
R.sub.10 and R.sub.11 are independently selected from hydrogen;
methyl; and ethyl; and wherein one and only one of R.sub.4, R.sub.5
and R.sub.6 is guanidinylamino; e) R.sub.7 is selected from
hydrogen; unsubstituted C.sub.1-C.sub.3 alkanyl, alkenyl or
alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted C.sub.1-C.sub.3
alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino;
C.sub.1-C.sub.3 alkylamino or C.sub.1-C.sub.3 dialkylamino and
halo; and enantiomers, optical isomers, stereoisomers,
diastereomers, tautomers, addition salts, biohydrolyzable amides
and esters, and pharmaceutical compositions containing such novel
compounds, and the use of such compounds for preventing or treating
disorders modulated by alpha-2 adrenoceptors.
2. A compound according to claim 1 wherein R.sub.6 is
guanidinylamino and R.sub.11 is hydrogen.
3. A compound according to claim 2 wherein B is
CR.sub.3.dbd.CR.sub.8, R.sub.1 is nil and D is CR.sub.2.
4. A compound according to claim 3 wherein: R.sub.2, R.sub.3, and
R.sub.8 are hydrogen. R.sub.4 is selected from hydrogen, methyl,
methoxy, fluoro, chloro, bromo and cyano; R.sub.5 is hydrogen;
R.sub.7 is selected from methyl, chloro, and bromo; and R.sub.10 is
selected from hydrogen, and methyl.
5. A compound according to claim 2 wherein B is NR.sub.9 and D is
CR.sub.2.
6. A compound according to claim 5 wherein R.sub.2, R.sub.9 and
R.sub.10 are each independently chosen from hydrogen and methyl;
R.sub.4 is selected from hydrogen, methyl, methoxy, fluoro, chloro,
bromo and cyano; R.sub.5 is hydrogen; and R.sub.7 is selected from
methyl, chloro, and bromo.
7. A compound according to claim 2 wherein B is S and D is
CR.sub.2, and R.sub.1 is nil.
8. A compound according to claim 7 wherein R.sub.2 and R.sub.10 are
each independently chosen from hydrogen and methyl; R.sub.4 is
selected from hydrogen, methyl, methoxy, fluoro, chloro, bromo and
cyano; R.sub.5 is hydrogen; and R.sub.7 is selected from hydrogen,
methyl, chloro, and bromo.
9. The compound according to claim 2, wherein: R.sub.4 is selected
from hydrogen; unsubstituted C.sub.1-C.sub.3 alkanyl, alkenyl or
alkynyl; unsubstituted C.sub.1-C.sub.3 alkylthio or alkoxy;
hydroxy; thio; nitro; cyano; amino; and C.sub.1-C.sub.2 alkylamino
or C.sub.1-C.sub.2 dialkylamino and halo; R.sub.5 is hydrogen; and
R.sub.7 is selected from hydrogen; unsubstituted C.sub.1-C.sub.3
alkanyl, alkenyl or alkynyl; unsubstituted C.sub.1-C.sub.3
alkylthio or alkoxy; and C.sub.1-C.sub.2 alkylamino or
C.sub.1-C.sub.2 dialkylamino; and halo.
10. The compound according to claim 1, wherein R.sub.5 is
guanidinylamino and R.sub.11 is hydrogen.
11. A compound according to claim 10 wherein B is
CR.sub.3.dbd.CR.sub.8, R.sub.1 is nil and D is CR.sub.2.
12. A compound according to claim 11 wherein: R.sub.2 is hydrogen;
R.sub.3 is selected from methyl, bromo, fluoro or hydrogen; R.sub.4
is selected from methyl, chloro and bromo; R.sub.7 is selected from
methyl, chloro, bromo, cyano, and methoxy; R.sub.8 is selected from
methyl, bromo, chloro, fluoro, cyano, methoxy or hydrogen; and
R.sub.10 is selected from hydrogen and methyl.
13. A compound according to claim 10 wherein B is S and D is
CR.sub.2 and R.sub.1 is nil.
14. A compound according to claim 13 wherein R.sub.2 and R.sub.10
are each independently selected from hydrogen and methyl; R.sub.4
is selected from methyl, chloro, and bromo; R.sub.6 is hydrogen;
and R.sub.7 is selected from hydrogen, methyl, methoxy, fluoro,
chloro, bromo and cyano.
15. The compound according to claim 1, wherein R.sub.4 is
guanidinylamino and R.sub.11 is hydrogen.
16 The compound of claim 15 wherein B is chosen from NR.sub.9,
CR.sub.3.dbd.CR.sub.8 and S.
17. The compound according to claim 16, wherein: R.sub.5, R.sub.6
and R.sub.7 are each independently selected from hydrogen; methyl;
ethyl; methoxy; methylthio; hydroxy; thio; cyano; amino and halo;
and R.sub.2 is hydrogen.
18. The compound according to claim 1, wherein the compound is:
[(8-Methylquinolin-7-yl)amino]guanidine; or
[(4-Methylbenzimidazol-5-yl)a- mino]guanidine.
19. A pharmaceutical composition comprising: (a) a safe and
effective amount of a compound of any of claims 1, 2, 10, 15 or 18;
and (b) a pharmaceutically-acceptable carrier.
20. A pharmaceutical composition comprising the compound of claim 1
and one or more actives chosen from the group consisting of an
antihistamine, antitussive, mast cell stabilizer, leukotriene
antagonist, expectorant/mucolytic, antioxidant or radical
inhibitor, steroid, bronchodilator, antiviral, analgesic,
antiinflammatory, gastrointestinal and ocular active.
21. A pharmaceutical composition according to claim 19 further
comprising an antihistamine.
22. A pharmaceutical composition according to claim 19 further
comprising an antiinflammatory.
23. A method for preventing or treating a disorder modulated by
alpha-2 adrenoceptors, by administering to a mammal in need of such
treatment, a safe and effective amount of an alpha-2 adrenoceptor
agonist compound according to claim 1.
24. A method for preventing or treating a disorder modulated by
alpha-2 adrenoceptors, wherein the disorder is chosen from the
groups comprising, nasal congestion, otitis media, sinusitis,
asthma, pain, migraine, substance abuse and addiction,
gastrointestinal disorder, ulcer, stomach hyperacidity, benign
prostatic hypertrophy, by administering to a mammal in need of such
treatment, a safe and effective amount of an alpha-2 adrenoceptor
agonist compound according to claim 1.
25. A method of treating or preventing nasal congestion by
administering to a mammal in need of such treatment a safe and
effective amount of a compound according to claim 1.
26. A method of treating or preventing nasal congestion by
administering to a mammal in need of such treatment a safe and
effective amount of a compound according to claim 18.
27. The method of claim 24, wherein the disorder is otitis
media.
28. The method of claim 24, wherein the disorder is sinusitis.
29. A method for preventing or treating a respiratory disorder,
wherein the disorder is chosen from the group comprising cough,
chronic obstructive pulmonary disease and asthma, by administering
to a mammal in need of such treatment, a safe and effective amount
of a compound according to claim 1.
30. A method for preventing or treating a respiratory disorder
according to claim 29, wherein the disorder is asthma.
31. A method for preventing or treating disorders mediated by
sympathetic activity and modulated by alpha-2 adrenoceptors by
administering to a mammal in need of such treatment, a safe and
effective amount of an alpha-2 adrenoceptor agonist compound
according to claim 1.
32. A method of treating a disorder according to claim 31, wherein
the disorder is chosen from the group comprising benign prostatic
hypertrophy, myocardial ischemia, cardiac reperfusion injury,
angina, cardiac arrhythmia, heart failure and hypertension.
33 The method of claim 32, wherein the disorder is heart
failure.
34. A method for preventing or treating an ocular disorder
modulated by alpha-2 adrenoceptors, by administering to a mammal in
need of such treatment, a safe and effective amount of a compound
according to claim 1.
35. A method for preventing or treating an ocular disorder
according to claim 34 wherein the disorder is chosen from the group
comprising ocular hypertension, glaucoma, hyperemia,
conjunctivitis, and uveitis and glaucoma.
36. A method for preventing or treating an ocular hypertensive
disorder according to claim 35 wherein the disorder is
glaucoma.
37. A method for preventing or treating a gastrointestinal disorder
modulated by alpha-2 adrenoceptors by administering to a mammal in
need of such treatment, a safe and effective amount of an alpha-2
adrenoceptor agonist compound according to claim 1.
38. A method for preventing or treating a gastrointestinal
disorder, according to claim 37, wherein the disorder is chosen
from the group comprising diarrhea and irritable bowel
syndrome.
39. A method for preventing or treating a gastrointestinal
disorder, according to claim 38, wherein the disorder is
diarrhea.
40. A method for preventing or treating migraine by administering
to a mammal in need of such treatment, a safe and effective amount
of a compound according to claim 1.
41. A method for preventing or treating pain by administering to a
mammal in need of such treatment, a safe and effective amount of a
compound according to claim 1.
42. A method for treating substance abuse by administering to a
mammal in need of such treatment, a safe and effective amount of a
compound according to claim 1.
Description
CROSS REFERENCE
[0001] This application claims priority under Title 35, United
States Code 119(e) from Provisional Application Ser. No.
60/031,833, filed Nov. 25, 1996.
TECHNICAL FIELD
[0002] This invention relates to certain substituted
guanidinylamino heterocycle compounds. The compounds have been
found to be alpha-2 adrenoceptor agonists and are useful for
treatment of disorders modulated by alpha-2 adrenoceptors.
BACKGROUND OF THE INVENTION
[0003] Therapeutic indications of alpha-2 adrenoceptor agonists
have been discussed in the literature: Ruffolo, R. R., A. J.
Nichols, J. M. Stadel, & J. P. Hieble, "Pharmacologic and
Therapeutic Applications of Alpha-2 Adrenoceptor Subtypes", Annual
Review of Pharmacology & Toxicology, Vol. 32 (1993) pp.
243-279.
[0004] Information regarding alpha adrenergic receptors, agonists
and antagonists, in general, and regarding compounds related in
structure to those of this invention are disclosed in the following
references: Timmermans, P. B. M. W. M., A. T. Chiu & M. J. M.
C. Thoolen, "12.1 .alpha.-Adrenergic Receptors", Comprehensive
Medicinal Chemistry, Vol. 3, Membranes & Receptors, P. G.
Sammes & J. B. Taylor, eds., Pergamon Press (1990), pp.
133-185; Timmermans, P. B. M. W. M. & P. A. van Zwieten,
".alpha.-Adrenoceptor Agonists and Antagonists", Drugs of the
Future, Vol. 9, No. 1, (January, 1984), pp. 41-55; Megens, A. A. H.
P., J. E. Leysen, F. H. L. Awouters & C. J. E. Niemegeers,
"Further Validation of in vivo and in vitro Pharmacological
Procedures for Assessing the .alpha..sub.1 and
.alpha..sub.2-Selectivity of Test Compounds: (2)
.alpha.-Adrenoceptor Agonists", European Journal of Pharmacology,
Vol. 129 (1986), pp. 57-64; Timmermans, P. B. M. W. M., A. de
Jonge, M. J. M. C. Thoolen, B. Wilffert, H. Batink & P. A. van
Zwieten, "Quantitative Relationships between .alpha.-Adrenergic
Activity and Binding Affinity of .alpha.-Adrenoceptor Agonists and
Antagonists", Journal of Medicinal Chemistry, Vol. 27 (1984) pp.
495-503; van Meel, J. C. A., A. de Jonge, P. B. M. W. M. Timmermans
& P. A. van Zwieten, "Selectivity of Some Alpha Adrenoceptor
Agonists for Peripheral Alpha-1 and Alpha-2 Adrenoceptors in the
Normotensive Rat", The Journal of Pharmacology and Experimental
Therapeutics, Vol. 219, No. 3 (1981), pp. 760-767; Chapleo, C. B.,
J. C. Doxey, P. L. Myers, M. Myers, C. F. C. Smith & M. R.
Stillings, "Effect of 1,4-Dioxanyl Substitution on the Adrenergic
Activity of Some Standard .alpha.-Adrenoreceptor Agents", European
Journal of Medicinal Chemistry, Vol. 24 (1989), pp. 619-622;
Chapleo, C. B., R. C. M. Butler, D. C. England, P. L. Myers, A. G.
Roach, C. F. C. Smith, M. R. Stillings & I. F. Tulloch,
"Heteroaromatic Analogues of the .alpha..sub.2-Adrenoreceptor
Partial Agonist Clonidine", Journal of Medicinal Chemistry, Vol. 32
(1989), pp. 1627-1630; Clare, K. A., M. C. Scrutton & N. T.
Thompson, "Effects of .alpha..sub.2-Adrenoceptor Agonists and of
Related Compounds on Aggregation of, and on Adenylate Cyclase
Activity in, Human Platelets", British Journal of Pharmacology,
Vol. 82 (1984), pp. 467-476; U.S. Pat. No. 3,890,319 issued to
Danielewicz, Snarey & Thomas on Jun. 17, 1975; and U.S. Pat.
No. 5,091,528 issued to Gluchowski on Feb. 25, 1992. However, many
compounds related in structure to those of this invention do not
provide the activity and specificity desirable when treating
disorders modulated by alpha-2 adrenoceptors.
[0005] For example, many compounds found to be effective nasal
decongestants are frequently found to have undesirable side
effects, such as causing hypertension and insomnia at systemically
effective doses. There is a need for new drugs which provide relief
from nasal congestion without causing these undesirable side
effects.
OBJECTS OF THE INVENTION
[0006] It is an object of the invention to provide compounds and
compositions useful in treating disorders modulated by alpha-2
adrenoceptors.
[0007] It is an object of this invention to provide novel compounds
having substantial activity in preventing or treating nasal
congestion, otitis media, and sinusitis, without undesired side
effects.
[0008] It is also an object of this invention to provide novel
compounds for treating cough, chronic obstructive pulmonary disease
(COPD) and/or asthma.
[0009] It is also an object of this invention to provide novel
compounds for treating diseases and disorders associated with
sympathetic nervous system activity, including benign prostatic
hypertrophy, cardiovascular disorders comprising myocardial
ischemia, cardiac reperfusion injury, angina, cardiac arrhythmia,
heart failure and hypertension.
[0010] It is also an object of this invention to provide novel
compounds for treating ocular disorders, such as ocular
hypertension, glaucoma, hyperemia, conjunctivitis and uveitis.
[0011] It is also an object of this invention to provide novel
compounds for treating gastrointestinal disorders, such as
diarrhea, irritable bowel syndrome, hyperchlorhydria (hyperacidity)
and peptic ulcer (ulcer).
[0012] It is also an object of this invention to provide novel
compounds for treating migraine.
[0013] It is also an object of this invention to provide novel
compounds for treating pain, substance abuse and/or withdrawal.
[0014] It is a still further object of this invention to provide
such compounds which have good activity from peroral, parenteral,
intranasal and/or topical dosing.
SUMMARY OF THE INVENTION
[0015] This invention relates to compounds having the following
structure: 2
[0016] a) R.sub.1 is hydrogen; or alkyl or nil; where R.sub.1 is
nil, bond (a) is a double bond;
[0017] b) D is CR.sub.2 where R.sub.2 is selected from hydrogen;
unsubstituted C.sub.1-C.sub.3 alkanyl; amino, hydroxy, mercapto;
C.sub.1-C.sub.3 alkylthio or alkoxy; C.sub.1-C.sub.3 alkylamino or
C.sub.1-C.sub.3 dialkylamino and halo; or when B is CR.sub.3, D may
be N;
[0018] c) B is NR.sub.9, CR.sub.3.dbd.CR.sub.8, CR.sub.3.dbd.N,
CR.sub.3, S, O, SO or SO.sub.2; wherein R.sub.9 is selected from
hydrogen; unsubstituted C.sub.1-C.sub.3 alkanyl, alkenyl or
alkynyl; cycloalkanyl, cycloalkenyl and wherein R.sub.3 and R.sub.8
are each independently selected from hydrogen; unsubstituted
C.sub.1-C.sub.3 alkanyl, alkenyl or alkynyl; cycloalkanyl,
cycloalkenyl; unsubstituted C.sub.1-C.sub.3 alkylthio or alkoxy;
hydroxy; thio; nitro; cyano; amino; C.sub.1-C.sub.3 alkylamino or
C.sub.1-C.sub.3 dialkylamino and halo;
[0019] d) R.sub.4, R.sub.5 and R.sub.6 are each independently
selected from hydrogen; unsubstituted C.sub.1-C.sub.3 alkanyl,
alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted
C.sub.1-C.sub.3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano;
amino; C.sub.1-C.sub.3 alkylamino or C.sub.1-C.sub.3 dialkylamino;
halo; and NH--NH--C(.dbd.NR.sub.10)NHR.sub.- 11 (guanidinylamino);
wherein R.sub.10 and R.sub.11 are independently selected from
hydrogen; methyl; and ethyl; and wherein one and only one of
R.sub.4, R.sub.5 and R.sub.6 is guanidinylamino;
[0020] e) R.sub.7 is selected from hydrogen; unsubstituted
C.sub.1-C.sub.3 alkanyl, alkenyl or alkynyl; cycloalkanyl,
cycloalkenyl; unsubstituted C.sub.1-C.sub.3 alkylthio or alkoxy;
hydroxy; thio; nitro; cyano; amino; C.sub.1-C.sub.3 alkylamino or
C.sub.1-C.sub.3 dialkylamino and halo;
[0021] and enantiomers, optical isomers, stereoisomers,
diastereomers, tautomers, addition salts, biohydrolyzable amides
and esters, and pharmaceutical compositions containing such novel
compounds, and the use of such compounds for preventing or treating
disorders modulated by alpha-2 adrenoceptors.
DETAILED DESCRIPTION OF THE INVENTION
[0022] As used herein, "alkanyl" means a saturated hydrocarbon
substituent, straight or branched chain, unsubstituted or
substituted.
[0023] As used herein, "alkenyl" means a hydrocarbon substituent
with one double bond, straight or branched chain, unsubstituted or
substituted.
[0024] As used herein, "alkylthio" means a substituent having the
structure Q--S--, where Q is alkanyl or alkenyl.
[0025] As used herein, "alkoxy" means a substituent having the
structure Q--O--, where Q is alkanyl or alkenyl.
[0026] As used herein, "alkylamino" means a substituent having the
structure Q--NH--, where 0 is alkanyl or alkenyl.
[0027] As used herein, "dialkylamino" means a substituent having
the structure Q.sub.1--N(Q.sub.2)--, where each Q is independently
alkanyl or alkenyl.
[0028] "Guanidinylamino" is defined as a radical of structure;
3
[0029] For purposes of exemplifying this radical, wherever it
appears in a chart, it is shown as "GNDNLAM" for brevity.
[0030] "Halo", "halogen", or "halide" is a chloro, bromo, fluoro or
iodo.
[0031] A "pharmaceutically-acceptable salt" is a cationic salt
formed at any acidic (e.g., carboxyl) group, or an anionic salt
formed at any basic (e.g., amino) group. Many such salts are known
in the art, as described in World Patent Publication 87/05297,
Johnston et al., published Sep. 11, 1987, incorporated by reference
herein. Preferred cationic salts include the alkali metal salts
(such as sodium and potassium), alkaline earth metal salts (such as
magnesium and calcium) and organic salts. Preferred anionic salts
include halides, sulfonates, carboxylates, phosphates, and the
like. Clearly contemplated in such salts are addition salts that
may provide an optical center, where once there was none. For
example, a chiral tartrate salt may be prepared from the compounds
of the invention, and this definition includes such chiral
salts.
[0032] The compounds of the invention are sufficiently basic to
form acid-addition salts. The compounds are useful both in the free
base form and the form of acid-addition salts, and both forms are
within the purview of the invention. The acid-addition salts are in
some cases a more convenient form for use. In practice, the use of
the salt form inherently amounts to the use of the base form of the
active. Acids used to prepare acid-addition salts include
preferably those which produce, when combined with the free base,
medicinally acceptable salts. These salts have anions that are
relatively innocuous to the animal organism, such as a mammal, in
medicinal doses of the salts so that the beneficial property
inherent in the free base are not vitiated by any side effects
ascribable to the acid's anions.
[0033] Examples of appropriate acid-addition salts include, but at
not limited to hydrochloride, hydrobromide, hydroiodiode, sulfate,
hydrogensulfate, acetate, trifluoroacetate, nitrate, maleate,
citrate, fumarate, formate, stearate, succinate, mallate, malonate,
adipate, glutarate, lactate, propionate, butyrate, tartrate,
methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate,
dodecyl sulfate, cyclohexanesulfamate, and the like. However, other
appropriate medicinally acceptable salts within the scope of the
invention are those derived from other mineral acids and organic
acids. The acid-addition salts of the basic compounds are prepared
by several methods. For example the free base can be dissolved in
an aqueous alcohol solution containing the appropriate acid and the
salt is isolated by evaporation of the solution. Alternatively,
they may be prepared by reacting the free base with an acid in an
organic solvent so that the salt separates directly. Where
separation of the salt is difficult, it can be precipitated with a
second organic solvent, or can be obtained by concentration of the
solution.
[0034] Although medicinally acceptable salts of the basic compounds
are preferred, all acid-addition salts are within the scope of the
present invention. All acid-addition salts are useful as sources of
the free base form, even if the particular salt per se is desired
only as an intermediate product. For example, when the salt is
formed only for purposes of purification or identification, or when
it is used as an intermediate in preparing a medicinally acceptable
salt by ion exchange procedures, these salts are clearly
contemplated to be a part of this invention.
[0035] "Biohydrolyzable amide" refers to an amide of the compound
of the invention that is readily converted in vivo by a mammal
subject to yield an active compound of the invention.
[0036] A "biohydrolyzable ester" refers to an ester of the compound
of the invention that is readily converted by a mammal subject to
yield an active compound of the invention.
[0037] "Optical isomer", "stereoisomer", "enantiomer,"
"diastereomer," as referred to herein have the standard art
recognized meanings (Cf., Hawleys Condensed Chemical Dictionary,
11th Ed.). Of course, an addition salt may provide an optical
center, where once there was none. For example, a chiral tartrate
salt may be prepared from the compounds of the invention, and this
definition includes such chiral salts. It will be apparent to the
skilled artisan that disclosure of the racemic mixture alone
discloses any enantiomers therein. Thus by one disclosure, more
than one compound is taught.
[0038] As used herein "animal" includes "mammals" which includes
"humans".
[0039] The skilled artisan will appreciate that tautomeric forms
will exist in certain compounds of the invention. For example, when
R.sub.2 is hydroxy and bond (a) is a double bond, it is understood
to include the keto form of that molecule, where R.sub.2 is oxo,
and bond (a) is a single bond, though not specifically described.
Thus, in this description the disclosure of one tautomeric form
discloses each and all of the tautomers. Similarly, when tautomer A
of the molecule is shown, it is understood to include tautomers B
and C of that molecule although not specifically depicted. 4
[0040] The illustration by scheme of example of specific protected
forms and other derivatives of the Formula (I) compounds is not
intended to be limiting. The application of other useful protecting
groups, salt forms, etc. is within the ability of the skilled
artisan.
[0041] As defined above and as used herein, substituent groups may
themselves be substituted. Such substitution may be with one or
more substituents. Such substituents include those listed in C.
Hansch and A. Leo, Substituent Constants for Correlation Analysis
in Chemistry and Biology (1979), incorporated by reference herein.
Preferred substituents include (for example) alkyl, alkenyl,
alkoxy, hydroxy, oxo, nitro, amino, aminoalkyl (e.g., aminomethyl,
etc.), cyano, halo, carboxy, alkoxyacetyl (e.g., carboethoxy,
etc.), thiol, aryl, cycloalkyl, heteroaryl, heterocycloalkyl (e.g.,
piperidinyl, morpholinyl, pyrrolidinyl, etc.), imino, thioxo,
hydroxyalkyl, aryloxy, arylalkyl, and combinations thereof.
[0042] For the purposes of nomenclature, as shown in the following
example, the location of the guanidinylamino radical is denoted:
5
[0043] It is recognized that where B is CR.sub.3.dbd.CR.sub.8,
CR.sub.3.dbd.N and the like, this numbering is not in strict
compliance with IUPAC nomenclature. It is used for illustration of
synthetic methods only; examples of compounds have names which more
closely resemble IUPAC nomenclature.
[0044] Compounds
[0045] This invention includes compounds having the following
structure: 6
[0046] as described in the Summary of the Invention.
[0047] In the above structure, when the guanidinylamino is at the
6-position, preferably R.sub.7 is selected from hydrogen;
unsubstituted alkanyl or alkenyl having from 1 to about 3 carbon
atoms; unsubstituted alkylthio or alkoxy having from 1 to about 3
carbon atoms; hydroxy; thiol; cyano; and halo. R.sub.4 is
preferably hydrogen, cyano, halo or methyl. R.sub.7 is also
preferably alkanyl, more preferably methyl or ethyl, most
preferably methyl. R.sub.7 which is alkylthio or alkoxy is
preferably saturated, also preferably C.sub.1 or C.sub.2, most
preferably methylthio or methoxy. R.sub.7 which is halo is
preferably chloro or bromo.
[0048] In the above structure, when the guanidinylamino is at the
5-position, preferably R.sub.4 is selected from hydrogen;
unsubstituted alkanyl or alkenyl having 1 to about 3 carbon atoms;
unsubstituted alkylthio or alkoxy having from 1 to about 3 carbon
atoms; hydroxy; thiol; cyano; and halo. R.sub.7 is preferably
alkanyl or halo. R.sub.4 and R.sub.7 are most preferably
methyl.
[0049] In the above structure, when the guanidinylamino is at the
4-position, preferably R.sub.7 is selected from hydrogen;
unsubstituted alkanyl or alkenyl having from 1 to about 3 carbon
atoms; hydroxy; thiol; cyano; and halo. R.sub.7 which is alkanyl,
is preferably methyl or ethyl, more preferably methyl. R.sub.7
which is halo is preferably chloro or bromo. R.sub.6 is preferably
hydrogen; alkanyl; cyano; and halo. R.sub.6 which is alkanyl is
preferably methyl or ethyl, most preferably methyl. R.sub.5 is
preferably hydrogen; alkanyl; and halo. R.sub.5 which is alkanyl is
preferably methyl or ethyl, most preferably methyl.
[0050] Methods of Making the Compounds of the Invention
[0051] The compounds of this invention are synthesized using the
following procedures. For purposes of this description,
6-guanidinylamino compounds are shown, but the skilled artisan will
appreciate that the 4- and 5-guanidinylamino compounds are prepared
similarly. The R.sub.1-R.sub.7 radicals are omitted for clarity,
unless they are prepared in that specific scheme. The skilled
artisan will appreciate that the radicals omitted are added using
techniques known in the art. The skilled artisan will also
appreciate that the methods described may be used with blocking
groups and the like, as appropriate.
[0052] Guanidinylamino groups are conveniently prepared from nitro
and amino compounds via the following example synthetic sequences:
7
[0053] Preferably these compounds are made from nitro or amino
compounds. (Nitro and amino compounds are made by known processes.)
The compounds may be manipulated to result in the suitably
substituted hydrazinoheterocycle. This hydrazinoheterocycle is then
reacted using known methods to produce the guanidinylamino
derivative. For example, the hydrazino compound may be reacted with
cyanamide (H.sub.2NCN) in acid to provide the guanidinylamino
compound. Alternatively, the hydrazino compound may be reacted with
a guanidine precursor, such as an alkyl pseudothiourea or protected
alkyl pseudothiourea in the presence of a mercuric salt or the
like.
[0054] The above starting nitro and amino compounds are obtained
via one or more synthetic steps comprising alkylations,
halogenations (usually brominations), and halogen displacement
reactions. Again, for clarity, the R.sub.1-R.sub.7 radicals are
omitted. In the schemes below, a 6-guanidinylamino precursor is
described. The skilled artisan will readily appreciate that
4-guanidinylamino and 5-guanidinylamino compounds are prepared by
analogous methods. These reaction types are summarized below;
[0055] Alkylation Reaction: 8
[0056] Fluorination: 9
[0057] Halogenation, Preferably Bromination: 10
[0058] Preferably, chlorination is accomplished using Cl.sub.2, and
iodination, by ICI using the same reactions.
[0059] Halogen Displacement Reactions: 11
[0060] It will be apparent to the skilled artisan that the
reactions illustrated above are known reactions. Furthermore, it is
within the purview of the skilled artisan to vary these reactions
to prepare compounds within the scope of the claims.
[0061] In the above schemes, where an R is alkoxy or alkylthio, the
corresponding hydroxy or thiol compounds are derived from the final
compounds by using a standard dealkylating procedure (Bhatt, et
al., "Cleavage of Ethers", Synthesis, 1983, pp. 249-281).
[0062] The starting materials used in preparing the compounds of
the invention are known, made by known methods, or are commercially
available as a starting material.
[0063] It is recognized that the skilled artisan in the art of
organic chemistry can readily carry out manipulations without
further direction, that is, it is well within the scope and
practice of the skilled artisan to carry out these manipulations.
These include reduction of carbonyl compounds to their
corresponding alcohols, oxidations, acylations, aromatic
substitutions, both electrophilic and nucleophilic,
etherifications, esterifications and saponifications and the like.
These manipulations are discussed in standard texts such as March,
Advanced Organic Chemistry (Wiley), Carey and Sundberg, Advanced
Organic Chemistry (2 vol.) and Trost and Fleming Comprehensive
Organic Synthesis (6 vol.). The skilled artisan will readily
appreciate that certain reactions are best carried out when other
functionality is masked or protected in the molecule, thus avoiding
any undesirable side reactions and/or increasing the yield of the
reaction. Often the skilled artisan utilizes protecting groups to
accomplish such increased yields or to avoid the undesired
reactions. These reactions are found in the literature and are also
well within the scope of the skilled artisan. Examples of many of
these manipulations are found, for example, in T. Greene,
Protecting Groups in Organic Synthesis.
COMPOUND EXAMPLES
[0064] The following non-limiting examples provide details for the
synthesis of
[0065] guanidinylamino heterocycles:
Example 1
[0066] [(8-Methylquinolin-7-yl)amino]guanidine
[0067] A. 8-Methyl-7-nitroquinoline.
[0068] To a suspension of 2 g of 2-methyl-3-nitroaniline and 1.02 g
of arsenic(V) oxide hydrate are added 2.88 mL of glycerin followed
by 1.09 mL of concentrated sulfuric acid. The resulting black
slurry is stirred at about 150.degree. C. for 4 hours. The black
oil is cooled to room temperature, diluted with water and poured
into a mixture of 25% aqueous ammonium hydroxide in ethyl acetate.
The organic layer is washed with water followed by brine. The
aqueous layers are extracted with ethyl acetate; the combined
organic layers are dried over magnesium sulfate, filtered and
rotary evaporated. The residue is purified by flash column
chromatography on silica gel, eluting with 50% ethyl
acetate/hexanes followed by recrystallization from
hexanes/methylene chloride to provide 1.45 g of
8-methyl-7-nitroquinoline as a pale brown solid.
[0069] B. 7-Amino-8-methylquinoline.
[0070] To a solution of 1.45 g of 8-methyl-7-nitroquinoline in 20
mL of ethanol are added 1.45 g of ammonium formate and a catalytic
amount of 10% palladium-on-carbon. The resulting suspension is
stirred at room temperature for 3 hours. The reaction mixture is
filtered on Celite, with a methanol wash of the solids, and the
filtrate is rotary evaporated. The residue is purified by flash
column chromatography on silica gel, eluting with 50% ethyl
acetate/hexanes followed by recrystallization from
hexanes/methylene chloride to provide 1.10 g of
7-amino-8-methylquinoline as a pale yellow solid.
[0071] C. [(8-Methylquinolin-7-yl)amino]guanidine, Dihydrochloric
Acid Salt
[0072] To a cold (-5.degree. C.) suspension of 400 mg of
7-amino-8-methylquinoline in 1 mL of concentrated hydrochloric acid
is added a cold (-5.degree. C.) solution of 192 mg of sodium
nitrite in 1 mL of water. The resulting suspension is stirred at
-5.degree. C. for 1 hour, and a solution of 1.05 g of stannous
chloride in 5 mL of concentrated hydrochloric acid is added at
once. A yellow precipitate forms immediately and the reaction
mixture is stirred at 0.degree. C. for 1 hour. The reaction mixture
is filtered to provide 341 mg of hydrazine hydrochloride as a
yellow solid.
[0073] To a mixture of the above hydrazine hydrochloride and 273 mg
of cyanamide are added 0.5 mL of concentrated hydrochloric acid and
0.2 mL of water. The resulting brown oil is stirred at 90.degree.
C. for 30 minutes. The reaction mixture is cooled to 0.degree. C.,
and 1 mL of water and 1 mL of concentrated hydrochloric acid are
added. A precipitate forms and the mixture is kept in the freezer
for 3-4 hours. The reaction mixture is then rotary evaporated and
the residue is dissolved in hot methanol and ethyl acetate is added
dropwise to the point of cloudiness. The solid that forms is
filtered to provide 320 mg of
[(8-methylquinolin-7-yl)amino]guanidine, dihydrochloric acid salt
as a yellow solid.
Example 2
[0074] [(4-Methylbenzimidazol-5-yl)amino]guanidine
[0075] A. 2,3-Diamino-6-nitrotoluene.
[0076] To a solution of 30 g of 3-methyl-2,4-dinitroaniline in 750
mL of boiling ethanol is added dropwise over 90 minutes a solution
of 109.6 g of sodium sulfide nonahydrate in 750 mL of water. At the
end of the addition, the mixture is heated to reflux for 30
minutes, then poured into ice (2000 g) and allowed to stand until
all the ice has melted. The mixture is then extracted with
methylene chloride and the organic layer is dried over magnesium
sulfate and rotary evaporated. The residue is purified by flash
column chromatography on silica gel, eluting with methylene
chloride to provide 2,3-diamino-6-nitrotoluene as an orange
solid.
[0077] B. 4-Methyl-5-nitrobenzimidazole.
[0078] A mixture of 11.8 g of 2,3-diamino-6-nitrotoluene, 390 mL of
88% formic acid and 38 mL of 12N hydrochloric acid is heated to
reflux for 1 hour. The resulting mixture is cooled to room
temperature and rotary evaporated. The residue is diluted with 200
mL of water, then basified with ammonium hydroxide (28-30%). The
suspension is extracted with ethyl acetate (3.times.200 mL). The
combined extracts are dried over magnesium sulfate and rotary
evaporated to provide 4-methyl-5-nitrobenzimidazole as an orange
solid.
[0079] C. 1-tert-Butoxycarbonyl-4-methyl-5-nitrobenzimidazole.
[0080] A suspension of 11.2 g of 4-methyl-5-nitrobenzimidazole,
21.58 g of di-tert-butyldicarbonate, 11.7 mL of triethylamine and
100 mg of 4-dimethylaminopyridine in methanol (800 mL) and ethyl
acetate (400 mL) is stirred at room temperature overnight. The
mixture is rotary evaporated and the residue purified by flash
column chromatography on silica gel, eluting with 10% ethyl acetate
in hexanes. The product-containing fractions are combined and
rotary evaporated to afford a white solid contaminated with a
yellow oil. The solid is dissolved in methylene chloride and enough
hexanes is added to cause precipitation. The solid is filtered and
washed with 50% methylene chloride/hexanes. The filtrate is rotary
evaporated and the process repeated until no more clean white solid
is obtained by precipitation. The combined solid fractions are
dried in vacuo to afford 1-tert-butoxycarbonyl-4-methyl-5-n-
itrobenzimidazole as a white solid.
[0081] D. 5-Amino-1-tert-butoxycarbonyl-4-methylbenzimidazole.
[0082] To a solution of 8 g of
1-tert-butoxycarbonyl-4-methyl-5-nitrobenzi- midazole in 40 mL of
methanol and 400 mL of ethyl acetate are added 500 mg of 10%
palladium-on-carbon and 7.27 g of ammonium formate. The mixture is
stirred at 50.degree. C. for 2 hours, then filtered on Celite, with
a methanol wash of the solids. The filtrate is rotary evaporated
and the residue partitioned between water and ethyl acetate. The
organic layer is washed with saturated ammonium chloride, dried
over magnesium sulfate, filtered and rotary evaporated to afford
5-amino-1-tert-butoxycarbonyl-4-- methylbenzimidazole as an
off-white solid.
[0083] E. [(4-Methylbenzimidazol-5-yl)amino]guanidine,
Dihydrochloric Acid Salt.
[0084] To a cold (-5.degree. C.) suspension of 500 mg of
1-(tert-butyloxycarbonyl)-5-amino-4-methylbenzimidazole in 1 mL of
concentrated hydrochloric acid is added a cold (-5.degree. C.)
solution of 154 mg of sodium nitrite in 0.5 mL of water. The
resulting suspension is stirred at -5.degree. C. for 15 minutes,
and a solution of 843 mg of stannous chloride in 5 mL of
concentrated hydrochloric acid is added at once. A white
precipitate immediately forms and the reaction mixture is stirred
at <0.degree. C. for 1 hour. The reaction mixture is filtered,
the residue is dissolved in methanol, and reprecipitated by adding
excess ether to provide the hydrazine hydrochloride as a white
solid.
[0085] To a mixture of the hydrazine hydrochloride and 340 mg of
cyanamide are added 0.5 mL of concentrated hydrochloric acid and
0.5 mL of water. The resulting pale yellow paste is stirred at
80.degree. C. for 1 hour. The reaction mixture is cooled to
0.degree. C., and 1 mL of water and 2 mL of concentrated
hydrochloric acid are added. A precipitate forms and the mixture is
kept in the freezer for 3-4 hours. The reaction mixture is rotary
evaporated and the residue is dissolved in hot methanol and ethyl
acetate is added dropwise to the point of cloudiness. The solid
that forms is filtered to provide 360 mg of
[(4-methylbenzimidazol-5-yl)amino]- guanidine, dihydrochloric acid
salt as an off-white solid.
[0086] Using the methodology outlined and exemplified above, the
following compounds are made. In these examples where R.sub.1 is
nil, (a) is a double bond guanidinylamino is signified by
GNDNLAM;
1 12 Example R.sub.1 D B R.sub.4 R.sub.5 R.sub.6 R.sub.7 In the
following table, R.sub.10 = R.sub.11 = hydrogen. 3 nil CH NH Cl H
GNDNLAM Me 4 nil CH NH Br H GNDNLAM Me 5 nil CH NH I H GNDNLAM Me 6
nil CH NH F H GNDNLAM Me 7 nil CH NH OMe H GNDNLAM Me 8 nil CH NH
Me H GNDNLAM Me 9 nil CH NH CN H GNDNLAM Me 10 nil CH NH Cl H
GNDNLAM Et 11 nil CH NH Br H GNDNLAM Et 12 nil CH NH I H GNDNLAM Et
13 nil CH NH F H GNDNLAM Et 14 nil CH NH Me H GNDNLAM Et 15 nil CH
NH H H GNDNLAM Et 16 nil CH NH Cl H GNDNLAM Br 17 nil CH NH Br H
GNDNLAM Br 18 nil CH NH I H GNDNLAM Br 19 nil CH NH F H GNDNLAM Br
20 nil CH NH OMe H GNDNLAM Br 21 nil CH NH Me H GNDNLAM Br 22 nil
CH NH CN H GNDNLAM Br 23 nil CH NH H H GNDNLAM Br 24 nil CH NH Cl H
GNDNLAM Cl 25 nil CH NH Br H GNDNLAM Cl 26 nil CH NH I H GNDNLAM Cl
27 nil CH NH F H GNDNLAM Cl 28 nil CH NH OMe H GNDNLAM Cl 29 nil CH
NH Me H GNDNLAM Cl 30 nil CH NH CN H GNDNLAM Cl 31 nil CH NH H H
GNDNLAM Cl 32 nil CH NH Cl H GNDNLAM OMe 33 nil CH NH Br H GNDNLAM
OMe 34 nil CH NH I H GNDNLAM OMe 35 nil CH NH F H GNDNLAM OMe 36
nil CH NH OMe H GNDNLAM OMe 37 nil CH NH Me H GNDNLAM OMe 38 nil CH
NH CN H GNDNLAM OMe 39 nil CH NH H H GNDNLAM OMe 40 nil CH NH Cl H
GNDNLAM SMe 41 nil CH NH Br H GNDNLAM SMe 42 nil CH NH I H GNDNLAM
SMe 43 nil CH NH F H GNDNLAM SMe 44 nil CH NH OMe H GNDNLAM SMe 45
nil CH NH Me H GNDNLAM SMe 46 nil CH NH CN H GNDNLAM SMe 47 nil CH
NH H H GNDNLAM SMe 48 nil CH NH H Me GNDNLAM Me 49 nil CH NH H Me
GNDNLAM Et 50 nil CH NH H Me GNDNLAM Br 51 nil CH NH H Me GNDNLAM
Cl 52 nil CH NH H Me GNDNLAM OMe 53 nil CH NH H Me GNDNLAM SMe 54
nil CH NH H OMe GNDNLAM Me 55 nil CH NH H OMe GNDNLAM Et 56 nil CH
NH H OMe GNDNLAM Br 57 nil CH NH H OMe GNDNLAM Cl 58 nil CH NH H
OMe GNDNLAM OMe 59 nil CH NH H OMe GNDNLAM SMe 60 nil CH NH H SMe
GNDNLAM Me 61 nil CH NH H SMe GNDNLAM Et 62 nil CH NH H SMe GNDNLAM
Br 63 nil CH NH H SMe GNDNLAM Cl 64 nil CH NH H SMe GNDNLAM OMe 65
nil CH NH H SMe GNDNLAM SMe 66 nil CH NH H Br GNDNLAM Me 67 nil CH
NH H Br GNDNLAM Et 68 nil CH NH H Br GNDNLAM Br 69 nil CH NH H Br
GNDNLAM Cl 70 nil CH NH H Br GNDNLAM OMe 71 nil CH NH H Br GNDNLAM
SMe 72 nil CH NH H Cl GNDNLAM Me 73 nil CH NH H Cl GNDNLAM Cl 74
nil CH NH Me Me GNDNLAM Me 75 nil CH NH Me Cl GNDNLAM Me 76 nil CH
NH Me Br GNDNLAM Me 77 nil CH NH Me I GNDNLAM Me 78 nil CHMe NH H H
GNDNLAM Me 79 nil CHMe NH H H GNDNLAM Et 80 nil CHMe NH H H GNDNLAM
OMe 81 nil CH NMe H H GNDNLAM Me 82 nil CH S H H GNDNLAM Me 83 nil
CH S Me H GNDNLAM Me 84 nil CH S OMe H GNDNLAM Me 85 nil CH S Br H
GNDNLAM Me 86 nil CH S Cl H GNDNLAM Me 87 nil CH S F H GNDNLAM Me
88 nil CH S I H GNDNLAM Me 89 nil CH S CN H GNDNLAM Me 90 nil CH S
H H GNDNLAM Et 91 nil CH S Me H GNDNLAM Et 92 nil CH S OMe H
GNDNLAM Et 93 nil CH S Br H GNDNLAM Et 94 nil CH S Cl H GNDNLAM Et
95 nil CH S F H GNDNLAM Et 96 nil CH S I H GNDNLAM Et 97 nil CH S
CN H GNDNLAM Et 98 nil CH S H H GNDNLAM OMe 99 nil CH S Me H
GNDNLAM OMe 100 nil CH S OMe H GNDNLAM OMe 101 nil CH S Br H
GNDNLAM OMe 102 nil CH S Cl H GNDNLAM OMe 103 nil CH S F H GNDNLAM
OMe 104 nil CH S I H GNDNLAM OMe 105 nil CH S CN H GNDNLAM OMe 106
nil CH S H H GNDNLAM SMe 107 nil CH S Me H GNDNLAM SMe 108 nil CH S
OMe H GNDNLAM SMe 109 nil CH S Br H GNDNLAM SMe 110 nil CH S Cl H
GNDNLAM SMe 111 nil CH S F H GNDNLAM SMe 112 nil CH S I H GNDNLAM
SMe 113 nil CH S CN H GNDNLAM SMe 114 nil CH S H H GNDNLAM Br 115
nil CH S Me H GNDNLAM Br 116 nil CH S OMe H GNDNLAM Br 117 nil CH S
Br H GNDNLAM Br 118 nil CH S Cl H GNDNLAM Br 119 nil CH S F H
GNDNLAM Br 120 nil CH S I H GNDNLAM Br 121 nil CH S CN H GNDNLAM Br
122 nil CH S H Me GNDNLAM H 123 nil CH S H OMe GNDNLAM H 124 nil CH
S H Br GNDNLAM H 125 nil CH S H Me GNDNLAM Me 126 nil CH S H OMe
GNDNLAM Me 127 nil CH S H Br GNDNLAM Me 128 nil CH S H Me GNDNLAM
Et 129 nil CH S H OMe GNDNLAM Et 130 nil CH S H Br GNDNLAM Et 131
nil CH S H Me GNDNLAM Br 132 nil CH S H OMe GNDNLAM Br 133 nil CH S
H Br GNDNLAM Br 134 nil CH S H Me GNDNLAM OMe 135 nil CH S H OMe
GNDNLAM OMe 136 nil CH S H Br GNDNLAM OMe 137 nil CH S H Me GNDNLAM
SMe 138 nil CH S H OMe GNDNLAM SMe 139 nil CH S H Br GNDNLAM SMe
140 H CH.dbd. .dbd.CH H H GNDNLAM Me 141 H CH.dbd. .dbd.C(Br) H H
GNDNLAM Me 142 H CH.sub.2 CH.sub.2 H H GNDNLAM Me 143 H N.dbd.
.dbd.CH H H GNDNLAM Me 144 H N.dbd. .dbd.CH H H GNDNLAM Et 145 H
N.dbd. .dbd.CH H H GNDNLAM Br 146 nil CH O H H GNDNLAM Me 147 nil
CH CH.dbd.CH Cl H GNDNLAM Me 148 nil CH CH.dbd.CH Br H GNDNLAM Me
149 nil CH CH.dbd.CH I H GNDNLAM Me 150 nil CH CH.dbd.CH F H
GNDNLAM Me 151 nil CH CH.dbd.CH OMe H GNDNLAM Me 152 nil CH
CH.dbd.CH Me H GNDNLAM Me 153 nil CH CH.dbd.CH CN H GNDNLAM Me 154
nil CH CH.dbd.CH Cl H GNDNLAM Et 155 nil CH CH.dbd.CH Br H GNDNLAM
Et 156 nil CH CH.dbd.CH I H GNDNLAM Et 157 nil CH CH.dbd.CH F H
GNDNLAM Et 158 nil CH CH.dbd.CH OMe H GNDNLAM Et 159 nil CH
CH.dbd.CH Me H GNDNLAM Et 160 nil CH CH.dbd.CH CN H GNDNLAM Et 161
nil CH CH.dbd.CH H H GNDNLAM Et 162 nil CH CH.dbd.CH Cl H GNDNLAM
Br 163 nil CH CH.dbd.CH Br H GNDNLAM Br 164 nil CH CH.dbd.CH I H
GNDNLAM Br 165 nil CH CH.dbd.CH F H GNDNLAM Br 166 nil CH CH.dbd.CH
OMe H GNDNLAM Br 167 nil CH CH.dbd.CH Me H GNDNLAM Br 168 nil CH
CH.dbd.CH CN H GNDNLAM Br 169 nil CH CH.dbd.CH H H GNDNLAM Br 170
nil CH CH.dbd.CH Cl H GNDNLAM Cl 171 nil CH CH.dbd.CH Br H GNDNLAM
Cl 172 nil CH CH.dbd.CH I H GNDNLAM Cl 173 nil CH CH.dbd.CH F H
GNDNLAM Cl 174 nil CH CH.dbd.CH OMe H GNDNLAM Cl 175 nil CH
CH.dbd.CH Me H GNDNLAM Cl 176 nil CH CH.dbd.CH CN H GNDNLAM Cl 177
nil CH CH.dbd.CH H H GNDNLAM Cl 178 nil CH CH.dbd.CH Cl H GNDNLAM
OMe 179 nil CH CH.dbd.CH Br H GNDNLAM OMe 180 nil CH CH.dbd.CH I H
GNDNLAM OMe 181 nil CH CH.dbd.CH F H GNDNLAM OMe 182 nil CH
CH.dbd.CH OMe H GNDNLAM OMe 183 nil CH CH.dbd.CH Me H GNDNLAM OMe
184 nil CH CH.dbd.CH CN H GNDNLAM OMe 185 nil CH CH.dbd.CH H H
GNDNLAM OMe 186 nil CH CH.dbd.CH Cl H GNDNLAM SMe 187 nil CH
CH.dbd.CH Br H GNDNLAM SMe 188 nil CH CH.dbd.CH I H GNDNLAM SMe 189
nil CH CH.dbd.CH F H GNDNLAM SMe 190 nil CH CH.dbd.CH OMe H GNDNLAM
SMe 191 nil CH CH.dbd.CH Me H GNDNLAM SMe 192 nil CH CH.dbd.CH CN H
GNDNLAM SMe 193 nil CH CH.dbd.CH H H GNDNLAM SMe 194 nil CH
CH.dbd.CH H Me GNDNLAM Me 195 nil CH CH.dbd.CH H Me GNDNLAM Et 196
nil CH CH.dbd.CH H Me GNDNLAM Br 197 nil CH CH.dbd.CH H Me GNDNLAM
Cl 198 nil CH CH.dbd.CH H Me GNDNLAM OMe 199 nil CH CH.dbd.CH H Me
GNDNLAM SMe 200 nil CH CH.dbd.CH H OMe GNDNLAM Me 201 nil CH
CH.dbd.CH H OMe GNDNLAM Et 202 nil CH CH.dbd.CH H OMe GNDNLAM Br
203 nil CH CH.dbd.CH H OMe GNDNLAM Cl 204 nil CH CH.dbd.CH H OMe
GNDNLAM OMe 205 nil CH CH.dbd.CH H OMe GNDNLAM SMe 206 nil CH
CH.dbd.CH H SMe GNDNLAM Me 207 nil CH CH.dbd.CH H SMe GNDNLAM Et
208 nil CH CH.dbd.CH H SMe GNDNLAM Br 209 nil CH CH.dbd.CH H SMe
GNDNLAM Cl 210 nil CH CH.dbd.CH H SMe GNDNLAM OMe 211 nil CH
CH.dbd.CH H SMe GNDNLAM SMe 212 nil CH CH.dbd.CH H Br GNDNLAM Me
213 nil CH CH.dbd.CH H Br GNDNLAM Et 214 nil CH CH.dbd.CH H Br
GNDNLAM Br 215 nil CH CH.dbd.CH H Br GNDNLAM Cl 216 nil CH
CH.dbd.CH H Br GNDNLAM OMe 217 nil CH CH.dbd.CH H Br GNDNLAM SMe
218 nil CH CH.dbd.CH H Cl GNDNLAM Me 219 nil CH CH.dbd.CH H Cl
GNDNLAM Cl 220 nil CH CH.dbd.CH Me Me GNDNLAM Me 221 nil CH
CH.dbd.CH Me Cl GNDNLAM Me 222 nil CH CH.dbd.CH Me Br GNDNLAM Me
223 nil CH CH.dbd.CH Me I GNDNLAM Me 224 nil CH CH.dbd.CH Me
GNDNLAM H Cl 225 nil CH CH.dbd.CH Me GNDNLAM H Br 226 nil CH
CH.dbd.CH Me GNDNLAM H I 227 nil CH CH.dbd.CH Me GNDNLAM H Me 228
nil CH CH.dbd.CH Et GNDNLAM H Cl 229 nil CH CH.dbd.CH Et GNDNLAM H
Br 230 nil CH CH.dbd.CH Et GNDNLAM H I 231 nil CH CH.dbd.CH Et
GNDNLAM H Me 232 nil CH CH.dbd.CH Br GNDNLAM H Cl 233 nil CH
CH.dbd.CH Br GNDNLAM H Br 234 nil CH CH.dbd.CH Br GNDNLAM H I 235
nil CH CH.dbd.CH Br GNDNLAM H Me 236 nil CH CH.dbd.CH Cl GNDNLAM H
Cl 237 nil CH CH.dbd.CH Cl GNDNLAM H Br 238 nil CH CH.dbd.CH Cl
GNDNLAM H I 239 nil CH CH.dbd.CH Cl GNDNLAM H Me 240 nil CH
CH.dbd.CH OMe GNDNLAM H Cl 241 nil CH CH.dbd.CH OMe GNDNLAM H Br
242 nil CH CH.dbd.CH OMe GNDNLAM H I 243 nil CH CH.dbd.CH OMe
GNDNLAM H Me 244 nil CH CH.dbd.CH SMe GNDNLAM H Cl 245 nil CH
CH.dbd.CH SMe GNDNLAM H Br 246 nil CH CH.dbd.CH SMe GNDNLAM H I 247
nil CH CH.dbd.CH SMe GNDNLAM H Me 248 nil CH CH.dbd.CH Me GNDNLAM
Me H 249 nil CH CH.dbd.CH Me GNDNLAM Br H 250 nil CH CH.dbd.CH Me
GNDNLAM Cl H 251 nil CH CH.dbd.CH Me GNDNLAM OMe H 252 nil CH
CH.dbd.CH Me GNDNLAM SMe H 253 nil CH CH.dbd.CH Et GNDNLAM Me H 254
nil CH CH.dbd.CH Et GNDNLAM Br H 255 nil CH CH.dbd.CH Et GNDNLAM Cl
H 256 nil CH CH.dbd.CH Et GNDNLAM OMe H 257 nil CH CH.dbd.CH Et
GNDNLAM SMe H 258 nil CH CH.dbd.CH Br GNDNLAM Me H 259 nil CH
CH.dbd.CH Br GNDNLAM Br H 260 nil CH CH.dbd.CH Br GNDNLAM Cl H 261
nil CH CH.dbd.CH Br GNDNLAM OMe H 262 nil CH CH.dbd.CH Br GNDNLAM
SMe H 263 nil CH CH.dbd.CH Cl GNDNLAM Me H 264 nil CH CH.dbd.CH Cl
GNDNLAM Br H 265 nil CH CH.dbd.CH Cl GNDNLAM Cl H 266 nil CH
CH.dbd.CH Cl GNDNLAM OMe H 267 nil CH CH.dbd.CH Cl GNDNLAM SMe H
268 nil CH CH.dbd.CH OMe GNDNLAM Me H 269 nil CH CH.dbd.CH OMe
GNDNLAM Br H 270 nil CH CH.dbd.CH OMe GNDNLAM Cl H 271 nil CH
CH.dbd.CH OMe GNDNLAM OMe H 272 nil CH CH.dbd.CH OMe GNDNLAM SMe H
273 nil CH CH.dbd.CH SMe GNDNLAM Me H 274 nil CH CH.dbd.CH SMe
GNDNLAM Br H 275 nil CH CH.dbd.CH SMe GNDNLAM OMe H 276 nil CH
CH.dbd.CH SMe GNDNLAM SMe H 277 nil CH CH.dbd.CH Me GNDNLAM Me Me
278 nil CH C(Me).dbd.CH Me GNDNLAM H Me 279 nil CH C(Br).dbd.CH Me
GNDNLAM H Me 280 nil CH C(Cl).dbd.CH Me GNDNLAM H Me 281 nil CH
C(F).dbd.CH Me GNDNLAM H Me 282 nil CH CH.dbd.C(Me) Me GNDNLAM H Me
283 nil CH CH.dbd.C(CN) Me GNDNLAM H Me 284 nil CH CH.dbd.C(Br) Me
GNDNLAM H Me 285 nil CH CH.dbd.C(Cl) Me GNDNLAM H Me 286 nil CH
CH.dbd.C(F) Me GNDNLAM H Me 287 nil CH S Me GNDNLAM H Me 288 nil CH
S Me GNDNLAM H Cl 289 nil CH S Me GNDNLAM H Br 290 nil CH S Me
GNDNLAM H I 291 nil CH S Me GNDNLAM H OMe 292 nil CH S Cl GNDNLAM H
Me 293 nil CH S Cl GNDNLAM H Cl 294 nil CH S Cl GNDNLAM H Br 295
nil CH S Cl GNDNLAM H I 296 nil CH S Cl GNDNLAM H OMe 297 nil CH S
Br GNDNLAM H Me 298 nil CH S Br GNDNLAM H Cl 299 nil CH S Br
GNDNLAM H Br 300 nil CH S Br GNDNLAM H I 301 nil CH S Br GNDNLAM H
OMe 302 nil CH S I GNDNLAM H Me 303 nil CH S I GNDNLAM H Cl 304 nil
CH S I GNDNLAM H Br 305 nil CH S I GNDNLAM H I 306 nil CH S I
GNDNLAM H OMe 307 nil CH S Et GNDNLAM H Me 308 nil CH S Et GNDNLAM
H Cl 309 nil CH S Et GNDNLAM H Br 310 nil CH S Et GNDNLAM H I 311
nil CH S Et GNDNLAM H OMe 312 nil CH S Me GNDNLAM Me H 313 nil CH S
Me GNDNLAM Cl H 314 nil CH S Me GNDNLAM Br H 315 nil CH S Me
GNDNLAM I H 316 nil CH S Cl GNDNLAM Cl H 317 nil CH S Me GNDNLAM Me
Me 318 nil CH S Me GNDNLAM Cl Me 319 nil CH S Me GNDNLAM Br Me 320
nil CH S Me GNDNLAM I Me 321 nil CH S Et GNDNLAM H Me 322 nil CH S
Et GNDNLAM H Me 323 H CH.dbd. .dbd.CH GNDNLAM H H H 324 H CH.dbd.
.dbd.CH GNDNLAM H H Me 325 H CH.dbd. .dbd.CH GNDNLAM H H Et 326 H
CH.dbd. .dbd.CH GNDNLAM H H CN 327 H CH.dbd. .dbd.CH GNDNLAM H H Br
328 H CH.dbd. .dbd.CH GNDNLAM H H Cl 329 H CH.dbd. .dbd.CH GNDNLAM
H H I 330 H CH.dbd. .dbd.CH GNDNLAM H Me H 331 H CH.dbd. .dbd.CH
GNDNLAM H CN H 332 H CH.dbd. .dbd.CH GNDNLAM H Br H 333 H CH.dbd.
.dbd.CH GNDNLAM H Cl H 334 H CH.dbd. .dbd.CH GNDNLAM H I H 335 H
CH.dbd. .dbd.C(Me) GNDNLAM H H H 336 H CH.dbd. .dbd.C(Et) GNDNLAM H
H H 337 H CH.dbd. .dbd.C(Br) GNDNLAM H H H 338 H CH.dbd. .dbd.C(Cl)
GNDNLAM H H H 339 H CH.dbd. .dbd.C(CN) GNDNLAM H H H 340 H CH.dbd.
.dbd.CH GNDNLAM Me H H 341 H CH.dbd. .dbd.CH GNDNLAM Br H H 342 H
CH.sub.2 CH.sub.2 GNDNLAM H H H In the following table, R.sub.10 =
Me and R.sub.11 = H. 343 nil CH NH H H GNDNLAM Me 344 nil CH NH H H
GNDNLAM Br 345 nil CH CH.dbd.CH H H GNDNLAM Me 346 nil CH CH.dbd.CH
Me GNDNLAM H Me 347 nil CH S H H GNDNLAM Me 348 nil CH S H H
GNDNLAM Br In the following table, R.sub.10 = Et and R.sub.11 = H.
349 nil CH N H H GNDNLAM Me 350 nil CH CH.dbd.CH H H GNDNLAM Me 351
nil CH CH.dbd.CH Me GNDNLAM H Me 352 nil CH S H H GNDNLAM Me 353
nil CH S H H GNDNLAM Br
[0087] Compositions
[0088] Another aspect of this invention is compositions which
comprise a safe and effective amount of a subject compound, or a
pharmaceutically-acceptable salt thereof, and a
pharmaceutically-acceptab- le carrier.
[0089] As used herein, "safe and effective amount" means an amount
of the subject compound sufficient to significantly induce a
positive modification in the condition to be treated, but low
enough to avoid serious side effects (at a reasonable benefit/risk
ratio), within the scope of sound medical judgment. A safe and
effective amount of the subject compound will vary with the age and
physical condition of the patient being treated, the severity of
the condition, the duration of the treatment, the nature of
concurrent therapy, the particular pharmaceutically-acceptable
carrier utilized, and like factors within the knowledge and
expertise of the attending physician.
[0090] Preparing a dosage form is within the purview of the skilled
artisan. Examples are provided for the skilled artisan, but are
non-limiting, and it is contemplated that the skilled artisan can
prepare variations of the compositions claimed.
[0091] Compositions of this invention preferably comprise from
about 0.0001% to about 99% by weight of the subject compound, more
preferably from about 0.01% to about 90% of the compound of the
invention. Depending upon the route of administration and attendant
bioavailability, solubility or dissolution characteristics of the
dosage form, the dosage form has preferably from about 10% to about
50%, also preferably from about 5% to about 10%, also preferably
from about 1% to about 5%, and also preferably from about 0.01% to
about 1% of the subject compound. The frequency of dosing of the
subject compound is dependent upon the pharmacokinetic properties
of each specific agent (for example, biological half-life) and can
be determined by the skilled artisan.
[0092] In addition to the subject compound, the compositions of
this invention contain a pharmaceutically-acceptable carrier. The
term "pharmaceutically-acceptable carrier", as used herein, means
one or more compatible solid or liquid filler diluents or
encapsulating substances which are suitable for administration to a
mammal. The term "compatible", as used herein, means that the
components of the composition are capable of being commingled with
the subject compound, and with each other, in a manner such that
there is no interaction which would substantially reduce the
pharmaceutical efficacy of the composition under ordinary use
situations. Preferably when liquid dose forms are used, the
compounds of the invention are soluble in the components of the
composition. Pharmaceutically-acceptable carriers must, of course,
be of sufficiently high purity and sufficiently low toxicity to
render them suitable for administration to the mammal being
treated.
[0093] Some examples of substances which can serve as
pharmaceutically-acceptable carriers or components thereof are
sugars, such as lactose, glucose and sucrose; starches, such as
corn starch and potato starch; cellulose and its derivatives, such
as sodium carboxymethyl cellulose, ethyl cellulose, and methyl
cellulose; powdered tragacanth; malt; gelatin; talc; solid
lubricants, such as stearic acid and magnesium stearate; calcium
sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame
oil, olive oil, corn oil and oil of theobroma; polyols such as
propylene glycol, glycerine, sorbitol, mannitol, and polyethylene
glycol; alginic acid; emulsifiers, such as the Tweens.RTM.; wetting
agents, such sodium lauryl sulfate; coloring agents; flavoring
agents; tableting agents, stabilizers; antioxidants; preservatives;
pyrogen-free water; isotonic saline; and phosphate buffer
solutions. The choice of a pharmaceutically-acceptable carrier to
be used in conjunction with the subject compound is basically
determined by the way the compound is to be administered. If the
subject compound is to be injected, the preferred
pharmaceutically-acceptable carrier is sterile, physiological
saline, with a blood-compatible suspending agent, the pH of which
has been adjusted to about 7.4.
[0094] If the preferred mode of administering the subject compound
is perorally, the preferred unit dosage form is therefore tablets,
capsules, lozenges, chewable tablets, and the like. Such unit
dosage forms comprise a safe and effective amount of the subject
compound, which is preferably from about 0.01 mg to about 350 mg,
more preferably from about 0.1 mg to about 35 mg, based on a 70 kg
person. The pharmaceutically-acceptable carrier suitable for the
preparation of unit dosage forms for peroral administration are
well-known in the art. Tablets typically comprise conventional
pharmaceutically-compatible adjuvants as inert diluents, such as
calcium carbonate, sodium carbonate, mannitol, lactose and
cellulose; binders such as starch, gelatin and sucrose;
disintegrants such as starch, alginic acid and croscarmelose;
lubricants such as magnesium stearate, stearic acid and talc.
Glidants such as silicon dioxide can be used to improve flow
characteristics of the powder mixture. Coloring agents, such as the
FD&C dyes, can be added for appearance. Sweeteners and
flavoring agents, such as aspartame, saccharin, menthol,
peppermint, and fruit flavors, are useful adjuvants for chewable
tablets. Capsules typically comprise one or more solid diluents
disclosed above. The selection of carrier components depends on
secondary considerations like taste, cost, and shelf stability,
which are not critical for the purposes of this invention, and can
be readily made by a person skilled in the art.
[0095] Peroral compositions also include liquid solutions,
emulsions, suspensions, and the like. The
pharmaceutically-acceptable carriers suitable for preparation of
such compositions are well known in the art. Such liquid oral
compositions preferably comprise from about 0.001% to about 5% of
the subject compound, more preferably from about 0.01% to about
0.5%. Typical components of carriers for syrups, elixirs, emulsions
and suspensions include ethanol, glycerol, propylene glycol,
polyethylene glycol, liquid sucrose, sorbitol and water. For a
suspension, typical suspending agents include methyl cellulose,
sodium carboxymethyl cellulose, Avicel.RTM. RC-591, tragacanth and
sodium alginate; typical wetting agents include lecithin and
polysorbate 80; and typical preservatives include methyl paraben
and sodium benzoate. Peroral liquid compositions may also contain
one or more components such as sweeteners, flavoring agents and
colorants disclosed above.
[0096] Other compositions useful for attaining systemic delivery of
the subject compounds include sublingual and buccal dosage forms.
Such compositions typically comprise one or more of soluble filler
substances such as sucrose, sorbitol and mannitol; and binders such
as acacia, microcrystalline cellulose, carboxymethyl cellulose and
hydroxypropyl methyl cellulose. Glidants, lubricants, sweeteners,
colorants, antioxidants and flavoring agents disclosed above may
also be included.
[0097] Compositions can also be used to deliver the compound to the
site where activity is desired: intranasal doses for nasal
decongestion, inhalants for asthma, and eye drops, gels and creams
for ocular disorders.
[0098] Preferred compositions of this invention include solutions
or emulsions, preferably aqueous solutions or emulsions comprising
a safe and effective amount of a subject compound intended for
topical intranasal administration. Such compositions preferably
comprise from about 0.001% to about 25% of a subject compound, more
preferably from about 0.01% to about 10%. Similar compositions are
preferred for systemic delivery of subject compounds by the
intranasal route. Compositions intended to deliver the compound
systemically by intranasal dosing preferably comprise similar
amounts of a subject compound as are determined to be safe and
effective by peroral or parenteral administration. Such
compositions used for intranasal dosing also typically include safe
and effective amounts of preservatives, such as benzalkonium
chloride and thimerosal and the like; chelating agents, such as
edetate sodium and others; buffers such as phosphate, citrate and
acetate; tonicity agents such as sodium chloride, potassium
chloride, glycerin, mannitol and others; antioxidants such as
ascorbic acid, acetylcystine, sodium metabisulfate and others;
aromatic agents; viscosity adjustors, such as polymers, including
cellulose and derivatives thereof, and polyvinyl alcohol and acids
and bases to adjust the pH of these aqueous compositions as needed.
The compositions may also comprise local anesthetics or other
actives. These compositions can be used as sprays, mists, drops,
and the like.
[0099] Other preferred compositions of this invention include
aqueous solutions, suspensions, and dry powders comprising a safe
and effective amount of a subject compound intended for atomization
and inhalation administration. Such compositions preferably
comprise from about 0.1% to about 50% of a subject compound, more
preferably from about 1% to about 20%; of course, the amount can be
altered to fit the circumstance of the patient contemplated and the
package. Such compositions are typically contained in a container
with attached atomizing means. Such compositions also typically
include propellants such as chlorofluorocarbons 12/11 and 12/114,
and more environmentally friendly fluorocarbons, or other nontoxic
volatiles; solvents such as water, glycerol and ethanol, these
include cosolvents as needed to solvate or suspend the active;
stabilizers such as ascorbic acid, sodium metabisulfite;
preservatives such as cetylpyridinium chloride and benzalkonium
chloride; tonicity adjustors such as sodium chloride; buffers; and
flavoring agents such as sodium saccharin. Such compositions are
useful for treating respiratory disorders, such as asthma and the
like.
[0100] Other preferred compositions of this invention include
aqueous solutions comprising a safe and effective amount of a
subject compound intended for topical intraocular administration.
Such compositions preferably comprise from about 0.0001% to about
5% of a subject compound, more preferably from about 0.01% to about
0.5%. Such compositions also typically include one or more of
preservatives, such as benzalkonium chloride, thimerosal,
phenylmercuric acetate; vehicles, such as poloxamers, modified
celluloses, povidone and purified water; tonicity adjustors, such
as sodium chloride, mannitol and glycerin; buffers such as acetate,
citrate, phosphate and borate; antioxidants such as sodium
metabisulfite, butylated hydroxy toluene and acetyl cysteine; acids
and bases may be used to adjust the pH of these formulations as
needed.
[0101] Other preferred compositions of this invention useful for
peroral administration include solids, such as tablets and
capsules, and liquids, such as solutions, suspensions and emulsions
(preferably in soft gelatin capsules), comprising a safe and
effective amount of a subject compound. Such compositions
preferably comprise from about 0.01 mg to about 350 mg per dose,
more preferably from about 0.1 mg to about 35 mg per dose. Such
compositions can be coated by conventional methods, typically with
pH or time-dependent coatings, such that the subject compound is
released in the gastrointestinal tract at various times to extend
the desired action. Such dosage forms typically include, but are
not limited to, one or more of cellulose acetate phthalate,
polyvinylacetate phthalate, hydroxypropyl methyl cellulose
phthalate, ethyl cellulose, Eudragit.RTM. coatings, waxes and
shellac.
[0102] Any of the compositions of this invention may optionally
include other drug actives. Non-limiting examples of drug actives
which may be incorporated in these compositions, include:
[0103] Antihistamines, Including;
[0104] Hydroxyzine, preferably at a dosage range of from about 25
to about 400 mg; Doxylamine, preferably at a dosage range of from
about 3 to about 75 mg; Pyrilamine, preferably at a dosage range of
from about 6.25 to about 200 mg; Chlorpheniramine, preferably at a
dosage range of from about 1 to about 24 mg; Phenindamine,
preferably at a dosage range of from about 6.25 to about 150 mg;
Dexchlorpheniramine, preferably at a dosage range of from about 0.5
to about 12 mg; Dexbrompheniramine, preferably at a dosage range of
from about 0.5 to about 12 mg; Clemastine, preferably at a dosage
range of from about 1 to about 9 mg; Diphenhydramine, preferably at
a dosage range of from about 6.25 to about 300 mg; Azelastine,
preferably at a dosage range of from about 140 to about 1,680 .mu.g
(when dosed intranasally); 1 to about 8 mg (when dosed orally);
Acrivastine, preferably at a dosage range of from about 1 to about
24 mg; Levocarbastine (which can be dosed as an intranasal or
ocular medicament), preferably at a dosage range of from about 100
to about 800 mg; Mequitazine, preferably at a dosage range of from
about 5 to about 20 mg; Astemizole, preferably at a dosage range of
from about 5 to about 20 mg; Ebastine, preferably at a dosage range
of from about 5 to about 20 mg; Loratadine, preferably at a dosage
range of from about 5 to about 40 mg; Cetirizine, preferably at a
dosage range of from about 5 to about 20 mg; Terfenadine,
preferably at a dosage range of from about 30 to about 480 mg;
Terfenadine metabolites; Promethazine, preferably at a dosage range
of from about 6.25 to about 50 mg; Dimenhydrinate, preferably at a
dosage range of from about 12.5 to about 400 mg; Meclizine,
preferably at a dosage range of from about 6.25 to about 50 mg;
Tripelennamine, preferably at a dosage range of from about 6.25 to
about 300 mg; Carbinoxamine, preferably at a dosage range of from
about 0.5 to about 16 mg; Cyproheptadine, preferably at a dosage
range of from about 2 to about 20 mg; Azatadine, preferably at a
dosage range of from about 0.25 to about 2 mg; Brompheniramine,
preferably at a dosage range of from about 1 to about 24 mg;
Triprolidine, preferably at a dosage range of from about 0.25 to
about 10 mg; Cyclizine, preferably at a dosage range of from about
12.5 to about 200 mg; Thonzylamine, preferably at a dosage range of
from about 12.5 to about 600 mg; Pheniramine, preferably at a
dosage range of from about 3 to about 75 mg; Cyclizine, preferably
at a dosage range of from about 12.5 to about 200 mg and
others;
[0105] Antitussives, Including;
[0106] Codeine, preferably at a dosage range of from about 2.5 to
about 120 mg; Hydrocodone, preferably at a dosage range of from
about 2.5 to about 40 mg; Dextromethorphan, preferably at a dosage
range of from about 2.5 to about 120 mg; Noscapine, preferably at a
dosage range of from about 3 to about 180 mg; Benzonatate,
preferably at a dosage range of from about 100 to about 600 mg;
Diphenhydramine, preferably at a dosage range of from about 12.5 to
about 150 mg; Chlophedianol, preferably at a dosage range of from
about 12.5 to about 100 mg; Clobutinol, preferably at a dosage
range of from about 20 to about 240 mg; Fominoben, preferably at a
dosage range of from about 80 to about 480 mg; Glaucine;
Pholcodine, preferably at a dosage range of from about 1 to about
40 mg; Zipeprol, preferably at a dosage range of from about 75 to
about 300 mg; Hydromorphone, preferably at a dosage range of from
about 0.5 to about 8 mg; Carbetapentane, preferably at a dosage
range of from about 15 to about 240 mg; Caramiphen, preferably at a
dosage range of from about 10 to about 100 mg; Levopropoxyphene,
preferably at a dosage range of from about 25 to about 200 mg and
others;
[0107] Antiinflammatories, Preferably Non-steroidal
Anti-inflammatories, (NSAIDS) Including;
[0108] Ibuprofen, preferably at a dosage range of from about 50 to
about 3,200 mg; Naproxen, preferably at a dosage range of from
about 62.5 to about 1,500 mg; Sodium naproxen, preferably at a
dosage range of from about 110 to about 1,650 mg; Ketoprofen,
preferably at a dosage range of from about 25 to about 300 mg;
Indoprofen, preferably at a dosage range of from about 25 to about
200 mg; Indomethacin, preferably at a dosage range of from about 25
to about 200 mg; Sulindac, preferably at a dosage range of from
about 75 to about 400 mg; Diflunisal, preferably at a dosage range
of from about 125 to about 1,500 mg; Ketorolac, preferably at a
dosage range of from about 10 to about 120 mg; Piroxicam,
preferably at a dosage range of from about 10 to about 40 mg;
Aspirin, preferably at a dosage range of from about 80 to about
4,000 mg; Meclofenamate, preferably at a dosage range of from about
25 to about 400 mg; Benzydamine, preferably at a dosage range of
from about 25 to about 200 mg; Carprofen, preferably at a dosage
range of from about 75 to about 300 mg; Diclofenac, preferably at a
dosage range of from about 25 to about 200 mg; Etodolac, preferably
at a dosage range of from about 200 to about 1,200 mg; Fenbufen,
preferably at a dosage range of from about 300 to about 900 mg;
Fenoprofen, preferably at a dosage range of from about 200 to about
3,200 mg; Flurbiprofen, preferably at a dosage range of from about
50 to about 300 mg; Mefenamic acid, preferably at a dosage range of
from about 250 to about 1,500 mg; Nabumetone, preferably at a
dosage range of from about 250 to about 2,000 mg; Phenylbutazone,
preferably at a dosage range of from about 100 to about 400 mg;
Pirprofen, preferably at a dosage range of from about 100 to about
800 mg; Tolmetin, preferably at a dosage range of from about 200 to
about 1,800 mg and others;
[0109] Analgesics, Including
[0110] Acetaminophen, preferably at a dosage range of from about 80
to about 4,000 mg; and others:
[0111] Expectorants/Mucolytics, Including;
[0112] Guaifenesin, preferably at a dosage range of from about 50
to about 2,400 mg; N-Acetylcysteine, preferably at a dosage range
of from about 100 to about 600 mg; Ambroxol, preferably at a dosage
range of from about 15 to about 120 mg; Bromhexine, preferably at a
dosage range of from about 4 to about 64 mg; Terpin hydrate,
preferably at a dosage range of from about 100 to about 1,200 mg;
Potassium iodide, preferably at a dosage range of from about 50 to
about 250 mg and others;
[0113] Anticholinergics (e.g. Atropinics), Preferably Intranasally
or Orally Administered Anticholinergics, Including;
[0114] Ipratroprium (preferably intranasally), preferably at a
dosage range of from about 42 to about 252 .mu.g; Atropine sulfate
(preferably oral), preferably at a dosage range of from about 10 to
about 1,000 .mu.g; Belladonna (preferably as an extract),
preferably at a dosage range of from about 15 to about 45 mg
equivalents; Scopolamine, preferably at a dosage range of from
about 400 to about 3,200 .mu.g; Scopolamine methobromide,
preferably at a dosage range of from about 2.5 to about 20 mg;
Homatropine methobromide, preferably at a dosage range of from
about 2.5 to about 40 mg; Hyoscyamine (preferably oral), preferably
at a dosage range of from about 125 to about 1,000 .mu.g;
Isopropramide (preferably oral), preferably at a dosage range of
from about 5 to about 20 mg; Orphenadrine (preferably oral),
preferably at a dosage range of from about 50 to about 400 mg;
Benzalkonium chloride (preferably intranasally) preferably a 0.005
to about 0.1% solution and others;
[0115] Mast Cell Stabilizers, Preferably Intranasally, or Orally
Administered Mast Cell Stabilizers, Including:
[0116] Cromalyn, preferably at a dosage range of from about 10 to
about 60 mg; Nedocromil, preferably at a dosage range of from about
10 to about 60 mg; Oxatamide, preferably at a dosage range of from
about 15 to about 120 mg; Ketotifen, preferably at a dosage range
of from about 1 to about 4 mg; Lodoxamide, preferably at a dosage
range of from about 100 to about 3,000 .mu.g and others;
[0117] Leukotriene Antagonists, Including Zileuton and Others;
[0118] Methylxanthines, Including;
[0119] Caffeine, preferably at a dosage range of from about 65 to
about 600 mg; Theophylline, preferably at a dosage range of from
about 25 to about 1,200 mg; Enprofylline; Pentoxifylline,
preferably at a dosage range of from about 400 to about 3,600 mg;
Aminophylline, preferably at a dosage range of from about 50 to
about 800 mg; Dyphylline, preferably at a dosage range of from
about 200 to about 1,600 mg and others;
[0120] Antioxidants or Radical Inhibitors, Including;
[0121] Ascorbic acid, preferably at a dosage range of from about 50
to about 10,000 mg; Tocopherol, preferably at a dosage range of
from about 50 to about 2,000 mg; Ethanol, preferably at a dosage
range of from about 500 to about 10,000 mg and others;
[0122] Steroids, Preferably Intranasally Administered Steroids,
Including:
[0123] Beclomethasone, preferably at a dosage range of from about
84 to about 336 .mu.g; Fluticasone, preferably at a dosage range of
from about 50 to about 400 .mu.g; Budesonide, preferably at a
dosage range of from about 64 to about 256 .mu.g; Mometasone,
preferably at a dosage range of from about 50 to about 300 mg;
Triamcinolone, preferably at a dosage range of from about 110 to
about 440 .mu.g; Dexamethasone, preferably at a dosage range of
from about 168 to about 1,008 .mu.g; Flunisolide, preferably at a
dosage range of from about 50 to about 300 .mu.g; Prednisone
(preferably oral), preferably at a dosage range of from about 5 to
about 60 mg; Hydrocortisone (preferably oral), preferably at a
dosage range of from about 20 to about 300 mg and others;
[0124] Bronchodilators, Preferably for Inhalation, Including;
[0125] Albuterol, preferably at a dosage range of from about 90 to
about 1,080 .mu.g; 2 to about 16 mg (if dosed orally); Epinephrine,
preferably at a dosage range of from about 220 to about 1,320
.mu.g; Ephedrine, preferably at a dosage range of from about 15 to
about 240 mg (if dosed orally); 250 to about 1,000 .mu.g (if dosed
intranasally); Metaproterenol, preferably at a dosage range of from
about 65 to about 780 .mu.g or 10 to about 80 mg if dosed orally;
Terbutaline, preferably at a dosage range of from about 200 to
about 2,400 .mu.g; 2.5 to about 20 mg (if dosed orally);
Isoetharine, preferably at a dosage range of from about 340 to
about 1,360 .mu.g; Pirbuterol, preferably at a dosage range of from
about 200 to about 2,400 .mu.g; Bitolterol, preferably at a dosage
range of from about 370 to about 2,220 .mu.g; Fenoterol, preferably
at a dosage range of from about 100 to about 1,200 .mu.g; 2.5 to
about 20 mg (if dosed orally); Rimeterol, preferably at a dosage
range of from about 200 to about 1,600 .mu.g; Ipratroprium,
preferably at a dosage range of from about 18 to about 216 .mu.g
(inhalation) and others; and
[0126] Antivirals, Including;
[0127] Amantadine, preferably at a dosage range of from about 50 to
about 200 mg; Rimantadine, preferably at a dosage range of from
about 50 to about 200 mg; Enviroxime; Nonoxinols, preferably at a
dosage range of from about 2 to about 20 mg (preferably an
intranasal form); Acyclovir, preferably at a dosage range of from
about 200 to about 2,000 mg (oral); 1 to about 10 mg (preferably an
intranasal form); Alpha-interferon, preferably at a dosage range of
from about 3 to about 36 MIU; Beta-interferon, preferably at a
dosage range of from about 3 to about 36 MIU and others;
[0128] Ocular Drug Actives:
[0129] acetylcholinesterase inhibitors, e.g., echothiophate from
about 0.03% to about 0.25% in topical solution and others; and
[0130] Gastrointestinal Actives:
[0131] antidiarrheals, e.g., Ioperamide from about 0.1 mg to about
1.0 mg per dose, and bismuth subsalicylate from about 25 mg to
about 300 mg per dose and others.
[0132] Of course, clearly contemplated and included in the
description above are the acid or base addition salts, esters,
metabolites, stereoisomers and enantiomers of these preferred
combination actives, as well as their analogues of these actives
that are safe and effective. It is also recognized that an active
may be useful for more than one of the above uses, and these uses
are clearly contemplated as well. This overlap is recognized in the
art and adjusting dosages and the like to fit the indication is
well within the purview of the skilled medical practitioner.
[0133] Methods of Use
[0134] Without being bound by theory, it is contemplated that the
primary mechanism by which alpha-2 agonists provide efficacy is by
intervening in the biological cascade responsible for disorder(s)
and/or manifestation(s) thereof. It may be that there is no deficit
in alpha-2 adrenoceptor activity: such activity may be normal.
However, administration of an alpha-2 agonist may be a useful way
of rectifying a disorder, condition or manifestation thereof.
[0135] Thus as used herein, the terms "disease," "disorder" and
"condition" are used interchangeably to refer to maladies related
to or modulated by alpha-2 adrenoceptor activity.
[0136] As used herein, a disorder described by the terms "modulated
by alpha-2 adrenoceptors," or "modulated by alpha-2 adrenoceptor
activity" refers to a disorder, condition or disease where alpha-2
adrenoceptor activity is an effective means of alleviating the
disorder or one or more of the biological manifestations of the
disease or disorder; or interferes with one or more points in the
biological cascade either leading to the disorder or responsible
for the underlying disorder; or alleviates one or more symptoms of
the disorder. Thus, disorders subject to "modulation" include those
for which:
[0137] The lack of alpha-2 activity is a "cause" of the disorder or
one or more of the biological manifestations, whether the activity
was altered genetically, by infection, by irritation, by internal
stimulus or by some other cause;
[0138] The disease or disorder or the observable manifestation or
manifestations of the disease or disorder are alleviated by alpha-2
activity. The lack of alpha-2 activity need not be causally related
to the disease or disorder or the observable manifestations
thereof;
[0139] Alpha-2 activity interferes with part of the biochemical or
cellular cascade that results in or relates to the disease or
disorder. In this respect, the alpha-2 activity alters the cascade,
and thus controls the disease, condition or disorder.
[0140] The compounds of this invention are particularly useful for
the treatment of nasal congestion associated with allergies, colds,
and other nasal disorders, as well as the sequelae of congestion of
the mucous membranes (for example, sinusitis and otitis media). At
effective doses, it has been found that undesired side effects can
be avoided.
[0141] While not limited to a particular mechanism of action, the
subject compounds are believed to provide advantages in the
treatment of nasal decongestion over related compounds through
their ability to interact with alpha-2 adrenoceptors. The subject
compounds have been found to be alpha-2 adrenoceptor agonists which
cause constriction of peripheral vascular beds in the nasal
turbinates.
[0142] Alpha-2 adrenoceptors are distributed both inside and
outside of the central nervous system. Thus, though not essential
for activity or efficacy, certain disorders preferably are treated
with compounds that act on alpha-2 adrenoceptors in only one of
these regions. Compounds of this invention vary in their ability to
penetrate into the central nervous system and, thus, to produce
effects mediated through central alpha-2 adrenoceptors. Thus, for
example, a compound which displays a higher degree of central
nervous system activity is preferred for central nervous system
indications over other compounds as described below. However, even
for compounds that exhibit primarily peripheral activity, central
nervous system actions can be evoked by an increase in the dose of
the compound. Further specificity of action of these compounds can
be achieved by delivering the agent to the region where activity is
desired (for example, topical administration to the eye, nasal
mucosa or respiratory tract).
[0143] Compounds preferred for, but not limited to, the treatment
of certain cardiovascular disorders, pain, substance abuse and/or
withdrawal, ulcer and hyperacidity include those compounds that are
centrally acting. By centrally acting what is meant is that they
have some action on the alpha-2 adrenoceptors in the central
nervous system in addition to their action at peripheral alpha-2
adrenoceptors.
[0144] Compounds preferred for, but not limited to, the treatment
of respiratory disorders, ocular disorders, migraine, certain
cardiovascular disorders, and certain other gastrointestinal
disorders are peripherally acting. By peripherally acting, what is
meant is that these compounds act primarily on alpha-2
adrenoceptors in the periphery, rather than those in the central
nervous system. Methods are available in the art to determine which
compounds are primarily peripherally acting and which are primarily
centrally acting.
[0145] Thus, compounds of the subject invention are also useful for
the treatment of ocular disorders such as ocular hypertension,
glaucoma, hyperemia, conjunctivitis, and uveitis. The compounds are
administered either perorally, or topically as drops, sprays,
mists, gels or creams directly to the surface of the mammalian
eye.
[0146] The compounds of this invention are also useful for
controlling gastrointestinal disorders, such as diarrhea, irritable
bowel syndrome, hyperchlorhydria and peptic ulcer.
[0147] The compounds of this invention are also useful for diseases
and disorders associated with sympathetic nervous system activity,
including hypertension, myocardial ischemia, cardiac reperfusion
injury, angina, cardiac arrhythmia, heart failure and benign
prostatic hypertrophy. Due to their sympatholytic effect, compounds
are also useful as an adjunct to anesthesia during surgical
procedures.
[0148] The compounds of this invention are also useful for
relieving pain associated with various disorders. The compounds are
administered perorally, parenterally, and/or by direct injection
into the cerebrospinal fluid.
[0149] The compounds of this invention are also useful for the
prophylactic or acute treatment of migraine. The compounds are
administered perorally, parenterally or intranasally.
[0150] The compounds of this invention are also useful for
treatment of substance abuse, in particular abuse of alcohol and
opiates, and alleviating the abstinence syndromes evoked by
withdrawal of these substances.
[0151] The compounds of this invention are also useful for other
diseases and disorders where vasoconstriction, particularly of
veins, would provide a benefit, including septic or cardiogenic
shock, elevated intracranial pressure, hemmorhoids, venous
insufficiency, varicose veins, and menopausal flushing.
[0152] The compounds of this invention are also useful for
neurologic diseases and disorders, including spasticity, epilepsy,
attention deficit hyperactive disorder, Tourette's syndrome, and
cognitive disorders.
[0153] The pharmacological activity and selectivity of these
compounds can be determined using published test procedures. The
alpha-2 selectivity of the compounds is determined by measuring
receptor binding affinities and in vitro functional potencies in a
variety of tissues known to possess alpha-2 and/or alpha-1
receptors. (See, e.g., The Alpha-2 Adrenergic Receptors, L. E.
Limbird, ed., Humana Press, Clifton, N.J.) The following in vivo
assays are typically conducted in rodents or other species. Central
nervous system activity is determined by measuring locomotor
activity as an index of sedation. (See, e.g., Spyraki, C. & H.
Fibiger, "Clonidine-induced Sedation in Rats: Evidence for
Mediation by Postsynaptic Alpha-2 Adrenoreceptors", Journal of
Neural Transmission, Vol. 54 (1982), pp. 153-163). Nasal
decongestant activity is measured using rhinomanometry as an
estimate of nasal airway resistance. (See, e.g., Salem, S. & E.
Clemente, "A New Experimental Method for Evaluating Drugs in the
Nasal Cavity", Archives of Otolaryngology, Vol. 96 (1972), pp.
524-529). Antiglaucoma activity is determined by measuring
intraocular pressure. (See, e.g., Potter, D., "Adrenergic
Pharmacology of Aqueous Human Dynamics", Pharmacological Reviews,
Vol. 13 (1981), pp. 133-153). Antidiarrheal activity is determined
by measuring the ability of the compounds to inhibit
prostaglandin-induced diarrhea. (See, e.g., Thollander, M., P.
Hellstrom & T. Svensson, "Suppression of Castor Oil-Induced
Diarrhea by Alpha-2 Adrenoceptor Agonists", Alimentary Pharmacology
and Therapeutics, Vol. 5 (1991), pp. 255-262). Efficacy in treating
irritable bowel syndrome is determined by measuring the ability of
compounds to reduce the stress-induced increase in fecal output.
(See, e.g., Barone, F., J. Deegan, W. Price, P. Fowler, J.
Fondacaro & H. Ormsbee III, "Cold-restraint stress increases
rat fecal pellet output and colonic transit", American Journal of
Physiology, Vol. 258 (1990), pp. G329-G337). Antiulcer and
reduction of hyperchlorhydria efficacy is determined by measuring
the reduction in gastric acid secretion produced by these compounds
(See, e.g., Tazi-Saad, K., J. Chariot, M. Del Tacca & C. Roze,
"Effect of .alpha.2-adrenoceptor agonists on gastric pepsin and
acid secretion in the rat", British Journal of Pharmacology, Vol.
106 (1992), pp. 790-796). Antiasthma activity is determined by
measuring the effect of the compound on bronchoconstriction
associated with pulmonary challenges such as inhaled antigens.
(See, e.g., Chang, J. J. Musser & J. Hand, "Effects of a Novel
Leukotriene D.sub.4 Antagonist with 5-Lipoxygenase and
Cyclooxygenase Inhibitory Activity, Wy-45,911, on
Leukotriene-D.sub.4- and Antigen-induced Bronchoconstriction in
Guinea Pig", International Archives of Allergy and Applied
Immunology, Vol. 86 (1988), pp. 48-54; and Delehunt, J., A.
Perruchound, L. Yerger, B. Marchette, J. Stevenson & W.
Abraham, "The Role of Slow-Reacting Substance of Anaphylaxis in the
Late Bronchial Response After Antigen Challenge in Allergic Sheep",
American Reviews of Respiratory Disease, Vol. 130 (1984), pp.
748-754). Activity in cough is determined by measuring the number
and latency of the cough response to respiratory challenges such as
inhaled citric acid. (See, e.g., Callaway, J. & R. King,
"Effects of Inhaled .alpha.2-Adrenoceptor and GABA.sub.B Receptor
Agonists on Citric Acid-induced Cough and Tidal Volume Changes in
Guinea Pigs", European Journal of Pharmacology, Vol. 220 (1992),
pp. 187-195). The sympatholytic activity of these compounds is
determined by measuring the reduction of plasma catecholamines
(See, e.g., R. Urban, B. Szabo & K. Starke "Involvement of
peripheral presynaptic inhibition in the reduction of sympathetic
tone by moxonidine, rilmenidine and UK 14,304", European Journal of
Pharmacology, Vol. 282 (1995), pp. 29-37) or the reduction in renal
sympathetic nerve activity (See, e.g., Feng, Q., S. Carlsson, P.
Thoren & T. Hedner, "Effects of clonidine on renal sympathetic
nerve activity, natriuresis and diuresis in chronic congestive
heart failure rats", Journal of Pharmacology and Experimental
Therapeutics, Vol. 261 (1992), pp. 1129-1135), providing the basis
for their benefit in heart failure and benign prostatic
hypertrophy. The hypotensive effect of these compounds is measure
directly as a reduction in mean blood pressure (See, e.g.,
Timmermans, P. & P. Van Zwieten, "Central and peripheral
.alpha.-adrenergic effects of some imidazolidines", European
Journal of Pharmacology, Vol. 45 (1977), pp. 229-236). Clinical
studies have demonstrated the beneficial effect of alpha-2 agonists
in the prevention of myocardial ischemia during surgery (See, e.g.,
Talke, P., J. Li, U. Jain, J. Leung, K. Drasner, M. Hollenberg
& D. Mangano, "Effects of Perioperative Dexmedetomidine
Infusion in Patients Undergoing Vascular Surgery", Anesthesiology,
Vol. 82 (1995), pp. 620-633) and in the prevention of angina (See,
e.g., Wright, R. A., P. Decroly, T. Kharkevitch & M. Oliver,
"Exercise Tolerance in Angina is Improved by Mivazerol--an
.alpha.2-Adrenoceptor Agonist", Cardiovascular Drugs and Therapy,
Vol. 7 (1993), pp. 929-934). The efficacy of these compounds in
cardiac reperfusion injury is demonstrated by measuring the
reduction of cardiac necrosis and neutrophil infiltration (See,
e.g., Weyrich, A., X. Ma, & A. Lefer, "The Role of L-Arginine
in Ameliorating Reperfusion Injury After Myocardial Ischemia in the
Cat", Circulation, Vol. 86 (1992), pp. 279-288). The cardiac
antiarrhythmic effect of these compounds is demonstrated by
measuring the inhibition of ouabain induced arrhythmias (See, e.g.,
Thomas, G. & P. Stephen, "Effects of Two Imidazolines (ST-91
and ST-93) on the Cardiac Arrhythmias and Lethality Induced by
Ouabain in Guinea-Pig", Asia-Pacific Journal of Pharmacology, Vol.
8 (1993), pp.109-113; and Samson, R., J. Cai, E. Shibata, J.
Martins & H. Lee, "Electrophysiological effects of
.alpha.2-adrenergic stimulation in canine cardiac Purkinje fibers",
American Journal of Physiology, Vol. 268 (1995), pp. H2024-H2035).
The vasoconstrictor activity of these compounds is demonstrated by
measuring the contractile properties on isolated arteries and veins
in vitro (See, e.g., Flavahan, N., T. Rimele, J. Cooke & M.
Vanhoutte, "Characterization of Postjunctional Alpha-1 and Alpha-2
Adrenoceptors Activated by Exogenous or Nerve-Released
Norepinephrine in the Canine Saphenous Vein", Journal of
Pharmacology and Experimental Therapeutics, Vol. 230 (1984), pp.
699-705). The effectiveness of these compounds at reducing
intracranial pressure is demonstrated by measurement of this
property in a canine model of subarachnoid hemorrhage (See, e.g.,
McCormick, J., P. McCormick, J. Zabramski & R. Spetzler,
"Intracranial pressure reduction by a central alpha-2
adrenoreceptor agonist after subarachnoid hemorrhage",
Neurosurgery, Vol. 32 (1993), pp. 974-979). The inhibition of
menopausal flushing is demonstrated by measuring the reduction of
facial blood flow in the rat (See, e.g., Escott, K., D. Beattie, H.
Connor & S. Brain, "The modulation of the increase in rat
facial skin blood flow observed after trigeminal ganglion
stimulation", European Journal of Pharmacology, Vol. 284 (1995),
pp. 69-76) as demonstrated for alpha-2 adrenergic agonists on
cutaneous blood flow in the tail (See, e.g., Redfern, W., M.
MacLean, R. Clague & J. McGrath, "The role of alpha-2
adrenoceptors in the vasculature of the rat tail", British Journal
of Pharmacology, Vol. 114 (1995), pp. 1724-1730). The
antinociceptive and pain reducing properties of these compounds is
demonstrated by measuring the increase in pain threshold in the
rodent writhing and hot plate antinociceptive models (See, e.g.,
Millan, M., K. Bervoets, J. Rivet, R. Widdowson, A. Renouard, S, Le
Marouille-Girardon & A. Gobert, "Multiple Alpha-2 Adrenergic
Receptor Subtypes. II. Evidence for a Role of Rat Alpha-2A
Adrenergic Receptors in the Control of Nociception, Motor Behavior
and Hippocampal Synthesis of Noradrenaline", Journal of
Pharmacology and Experimental Therapeutics, Vol. 270 (1994), pp.
958-972). The antimigraine effect of these compounds is
demonstrated by measuring the reduction of dural neurogenic
inflammation to trigeminal ganglion stimulation in the rat (See,
e.g., Matsubara, T., M. Moskowitz & Z. Huang, "UK-14,304,
R(-)-alpha-methyl-histamine and SMS 201-995 block plasma protein
leakage within dura mater by prejunctional mechanisms", European
Journal of Pharmacology, Vol. 224 (1992), pp. 145-150). The ability
of these compounds to suppress opiate withdrawal is demonstrated by
measuring the suppression of enhanced sympathetic nerve activity
(See, e.g., Franz, D., D. Hare & K. McCloskey, "Spinal
sympathetic neurons: possible sites of opiate-withdrawal
suppression by clonidine", Science, Vol. 215 (1982), pp.
1643-1645). Antiepileptic activity of these compounds is
demonstrated by measuring the inhibition of the kindling response
(See, e.g., Shouse, M., M. Bier, J. Langer, O. Alcalde, M. Richkind
& R. Szymusiak, "The .alpha.2-agonist clonidine suppresses
seizures, whereas the alpha-2 antagonist idazoxan promotes
seizures--a microinfusion study in amygdala-kindled kittens", Brain
Research, Vol. 648 (1994), pp. 352-356). The effectiveness of other
alpha-2 agonists in the management of neurologic disorders has been
demonstrated, including attention-deficit hyperactive disorder and
Tourette's syndrome (See, e.g., Chappell P., M. Riddle, L. Scahill,
K. Lynch, R. Schultz, A. Arnsten, J. Leckman & D. Cohen,
"Guanfacine treatment of comorbid attention-deficit hyperactivity
disorder and Tourette's syndrome: preliminary clinical experience",
Journal of American Academy of Child and Adolescent Psychiatry,
Vol. 34 (1995), pp. 1140-1146), cognitive disorders (See, e.g.,
Coull, J., "Pharmacological manipulations of the
.alpha.2-noradrenergic system. Effects on cognition", Drugs and
Aging, Vol. 5 (1994), pp. 116-126), and spasticity (See, e.g.,
Eyssette, M., F. Rohmer, G. Serratrice, J. Warter & D. Boisson,
"Multicenter, double-blind trial of a novel antispastic agent,
tizanidine, in spasticity associated with multiple sclerosis",
Current Medical Research & Opinion, Vol. 10 (1988), pp.
699-708).
[0154] Another aspect of this invention involves methods for
preventing or treating nasal congestion by administering a safe and
effective amount of a subject compound to a mammal experiencing or
at risk of experiencing nasal congestion. Such nasal congestion may
be associated with human diseases or disorders which include, but
are not limited to, seasonal allergic rhinitis, acute upper
respiratory viral infections, sinusitis, perennial rhinitis, and
vasomotor rhinitis. In addition, other disorders can be generally
associated with mucous membrane congestion (for example, otitis
media and sinusitis.) Each administration of a dose of the subject
compound preferably administers a dose within the range of from
about 0.0001 mg/kg to about 5 mg/kg of a compound, more preferably
from about 0.001 mg/kg to about 0.5 mg/kg. Peroral administration
of such doses is preferred. The frequency of administration of a
subject compound according to this invention is preferably from
about once to about six times daily, more preferably from about
once to about 4 times daily. Such doses and frequencies are also
preferred for treating other respiratory conditions, such as,
cough, chronic obstructive pulmonary disease (COPD) and asthma.
Such doses and frequencies are also preferred for treating
conditions that are associated with mucous membrane congestion (for
example, sinusitis and otitis media).
[0155] Another aspect of this invention involves methods for
preventing or treating glaucoma by administering a safe and
effective amount of a subject compound to a mammal experiencing or
at risk of experiencing glaucoma. If administered systemically,
each administration of a dose of the subject compound preferably
administers a dose within the range of from about 0.0001 mg/kg to
about 5 mg/kg of a compound, more preferably from about 0.001 mg/kg
to about 0.5 mg/kg. If intraocular dosing is used then preferably
one administers a typical volume (for example, 1 or 2 drops) of a
liquid composition, comprising from about 0.0001% to about 5% of a
subject compound, more preferably from about 0.01% to about 0.5% of
the compound. Determination of the exact dosage and regimen is
within the purview of the skilled artisan. Intraocular
administration of such doses is preferred. The frequency of
administration of a subject compound according to this invention is
preferably from about once to about six times daily, more
preferably from about once to about 4 times daily.
[0156] Another aspect of this invention involves methods for
preventing or treating gastrointestinal disorders, such as
diarrhea, irritable bowel syndrome, and peptic ulcer by
administering a safe and effective amount of a subject compound to
a mammal experiencing or at risk of experiencing gastrointestinal
disorders. Each administration of a dose of the subject compound
preferably administers a dose within the range of from about 0.0001
mg/kg to about 5 mg/kg of a compound, more preferably from about
0.001 mg/kg to about 0.5 mg/kg. Peroral administration of such
doses is preferred. The frequency of administration of a subject
compound according to this invention is preferably from about once
to about six times daily, more preferably from about once to about
4 times daily.
[0157] Another aspect of this invention involves methods for
preventing or treating migraine, by administering a safe and
effective amount of a subject compound to a mammal experiencing or
at risk of experiencing migraine. Each administration of a dose of
the subject compound preferably administers a dose within the range
of from about 0.0001 mg/kg to about mg/kg of a compound, more
preferably from about 0.001 mg/kg to about 0.5 mg/kg. Peroral,
parenteral or intranasal administration of such doses is preferred.
The frequency of peroral administration of a subject compound
according to this invention is preferably from about once to about
six times daily, more preferably from about once to about 4 times
daily. The frequency of parenteral dosing of a subject compound
according to this invention is preferably from about once to about
six times daily, more preferably from about once to about 4 times
daily or by infusion to the desired effect. The frequency of
intranasal dosing of a subject compound according to this invention
is preferably from about once to about six times daily, more
preferably from about once to about 4 times daily.
[0158] Another aspect of this invention involves methods for
preventing or treating disorders related to sympathetic nervous
system activity, such as hypertension, myocardial ischemia, cardiac
reperfusion injury, angina, cardiac arrhythmia, and benign
prostatic hypertrophy, by administering a safe and effective amount
of a subject compound to a mammal experiencing or at risk of
experiencing these diseases or disorders. Each administration of a
dose of the subject compound preferably administers a dose within
the range of from about 0.0001 mg/kg to about 5 mg/kg of a
compound, more preferably from about 0.001 mg/kg to about 0.5
mg/kg. Peroral and parenteral administration of such doses are
preferred. The frequency of peroral administration of a subject
compound according to this invention is preferably from about once
to about six times daily, more preferably from about once to about
4 times daily. The frequency of parenteral dosing of a subject
compound according to this invention is preferably from about once
to about six times daily, more preferably from about once to about
4 times daily or by infusion to the desired effect.
[0159] Another aspect of this invention involves methods for
preventing or treating pain, by administering a safe and effective
amount of a subject compound to a mammal experiencing or at risk of
experiencing pain. Each administration of a dose of the subject
compound preferably administers a dose within the range of from
about 0.0001 mg/kg to about 5 mg/kg of a compound, more preferably
from about 0.001 mg/kg to about 0.5 mg/kg. Peroral or parenteral
administration of such doses is preferred. The frequency of peroral
administration of a subject compound according to this invention is
preferably from about once to about six times daily, more
preferably from about once to about 4 times daily. The frequency of
parenteral dosing of a subject compound according to this invention
is preferably from about once to about six times daily, more
preferably from about once to about 4 times daily or by infusion to
the desired effect.
[0160] Another aspect of this invention involves methods for
preventing or treating substance abuse and the abstinence syndrome
resulting from withdrawal of these substances, such as alcohol and
opiates, by administering a safe and effective amount of a subject
compound to a mammal experiencing or at risk of experiencing
substance abuse or withdrawal symptoms. Each administration of a
dose of the subject compound preferably administers a dose within
the range of from about 0.0001 mg/kg to about 5 mg/kg of a
compound, more preferably from about 0.001 mg/kg to about 0.5
mg/kg. Peroral administration of such doses is preferred. The
frequency of administration of a subject compound according to this
invention is preferably from about once to about six times daily,
more preferably from about once to about 4 times daily.
COMPOSITION AND METHOD EXAMPLES
[0161] The following non-limiting examples illustrate the
compositions and methods of use of this invention.
Example A
Oral Tablet Composition
[0162]
2EXAMPLE A Oral Tablet Composition Ingredient Amount per tablet
(mg) Subject Compound 2 20.0 Microcrystalline cellulose (Avicel PH
102 .RTM.) 80.0 Dicalcium phosphate 96.0 Pyrogenic silica
(Cab-O-Sil .RTM.) 1.0 Magnesium stearate 3.0 Total = 200.0 mg
[0163] One tablet is swallowed by a patient with nasal congestion.
The congestion is substantially diminished.
[0164] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example B
Chewable Tablet Composition
[0165]
3EXAMPLE B Chewable Tablet Composition Ingredient Amount per tablet
(mg) Subject Compound 1 15.0 Mannitol 255.6 Microcrystalline
cellulose (Avicel PH 101 .RTM.) 100.8 Dextrinized sucrose (Di-Pac
.RTM.) 199.5 Imitation orange flavor 4.2 Sodium saccharin 1.2
Stearic acid 15.0 Magnesium stearate 3.0 FD&C Yellow #6 dye 3.0
Pyrogenic silica (Cab-O-Sil .RTM.) 2.7 Total = 600.0 mg
[0166] One tablet is chewed and swallowed by a patient with nasal
congestion. The congestion is substantially reduced.
[0167] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example C
Sublingual Tablet Composition
[0168]
4EXAMPLE C Sublingual Tablet Composition Ingredient Amount per
tablet (mg) Subject Compound 2 2.00 Mannitol 2.00 Microcrystalline
cellulose (Avicel PH 101 .RTM.) 29.00 Mint flavorants 0.25 Sodium
saccharin 0.08 Total = 33.33 mg
[0169] One tablet is placed under the tongue of a patient with
nasal congestion and allowed to dissolve. The congestion is rapidly
and substantially diminished.
[0170] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example D
Intranasal Solution Composition
[0171]
5EXAMPLE D Intranasal Solution Composition Ingredient Composition
(% w/v) Subject Compound 1 0.20 Benzalkonium chloride 0.02
Thimerosal 0.002 d-Sorbitol 5.00 Glycine 0.35 Aromatics 0.075
Purified water q.s. Total = 100.00
[0172] One-tenth of a mL of the composition is sprayed from a pump
actuator into each nostril of a patient with nasal congestion. The
congestion is substantially diminished.
[0173] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example E
Intranasal Gel Composition
[0174]
6EXAMPLE E Intranasal Gel Composition Ingredient Composition (%
w/v) Subject Compound 1 0.10 Benzalkonium chloride 0.02 Thimerosal
0.002 Hydroxypropyl methylcellulose 1.00 (Metolose 65SH4000 .RTM.)
Aromatics 0.06 Sodium chloride (0.65%) q.s. Total = 100.00
[0175] One-fifth of a mL of the composition is applied as drops
from a dropper into each nostril of a patient with nasal
congestion. The congestion is substantially reduced.
[0176] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example F
Inhalation Aerosol Composition
[0177]
7EXAMPLE F Inhalation Aerosol Composition Ingredient Composition (%
w/v) Subject Compound 2 5.0 Alcohol 33.0 Ascorbic acid 0.1 Menthol
0.1 Sodium Saccharin 0.2 Propellant (F12, F114) q.s. Total =
100.0
[0178] Two-puffs of the aerosol composition is inhaled from a
metered-dose inhaler by a patient with asthma. The asthmatic
condition is effectively relieved.
[0179] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example G
Topical Ophthalmic Composition
[0180]
8EXAMPLE G Topical Ophthalmic Composition Ingredient Composition (%
w/v) Subject Compound 1 0.10 Benzalkonium chloride 0.01 EDTA 0.05
Hydroxyethylcellulose (Natrosol M .RTM.) 0.50 Sodium metabisulfite
0.10 Sodium chloride (0.9%) q.s. Total = 100.0
[0181] One-tenth of a mL of the composition is administered
directly into each eye of a patient with glaucoma. The intraocular
pressure is substantially reduced.
[0182] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example H
Oral Liquid Composition
[0183]
9EXAMPLE H Oral Liquid Composition Ingredient Amount/15 mL Dose
Subject Compound 2 15 mg Chlorpheniramine maleate 4 mg Propylene
glycol 1.8 g Ethanol (95%) 1.5 mL Methanol 12.5 mg Eucalyptus oil
7.55 mg Flavorants 0.05 mL Sucrose 7.65 g Carboxymethylcellulose
(CMC) 7.5 mg Microcrystalline cellulose and 187.5 mg Sodium CMC
(Avicel RC 591 .RTM.) Polysorbate 80 3.0 mg Glycerin 300 mg
Sorbitol 300 mg FD&C Red #40 dye 3 mg Sodium saccharin 22.5 mg
Sodium phosphate monobasic 44 mg Sodium citrate monohydrate 28 mg
Purified Water q.s. Total = 15 mL
[0184] One 15 mL dose of the liquid composition is swallowed by a
patient with nasal congestion and runny nose due to allergic
rhinitis. The congestion and runny nose are effectively
reduced.
[0185] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example J
Oral Liquid Composition
[0186]
10EXAMPLE J Oral Liquid Composition Ingredient Amount/15 mL Dose
Subject Compound 2 30 mg Sucrose 8.16 g Glycerin 300 mg Sorbitol
300 mg Methylparaben 19.5 mg Propylparaben 4.5 mg Menthol 22.5 mg
Eucalyptus oil 7.5 mg Flavorants 0.07 mL FD&C Red #40 dye 3.0
mg Sodium saccharin 30 mg Purified water q.s. Total = 15 mL
[0187] One 15 mL dose of the alcohol-free liquid medication is
swallowed by a patient with nasal congestion. The congestion is
substantially diminished.
[0188] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example K
Oral Tablet Composition
[0189]
11EXAMPLE K Oral Tablet Composition Ingredient Amount per tablet
(mg) Subject Compound 1 4 Microcrystalline cellulose, NF 130 Starch
1500, NF 100 Magnesium stearate, USP 2 Total = 236 mg
[0190] One tablet is swallowed by a patient with migraine. The pain
and aura of migraine is substantially diminished.
[0191] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example L
Oral Tablet Composition
[0192]
12EXAMPLE L Oral Tablet Composition Ingredient Amount per tablet
(mg) Subject Compound 2 12 Hydroxypropyl methylcellulose, USP 12
Magnesium stearate, USP 2 Lactose anhydrous, USP 200 Total = 226
mg
[0193] For the relief of pain. Adults 12 and over take one tablet
every twelve hours.
[0194] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example M
Oral Caplet Composition
[0195]
13EXAMPLE M Oral Caplet Composition Ingredient Amount per tablet
(mg) Naproxen sodium anhydrous, USP 220 Subject Compound 1 6
Hydroxypropyl methylcellulose, USP 6 Magnesium stearate, USP 2
Povidone K-30, USP 10 Talc, USP 12 Microcrystalline cellulose, NF
44 Total = 300 mg
[0196] For relief of symptoms associated with the common cold,
sinusitis, or flu including nasal congestion, headache, fever, body
aches, and pains. Adults 12 and over take two caplets every twelve
hours.
[0197] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example N
Oral Tablet Composition
[0198]
14EXAMPLE N Oral Tablet Composition Ingredient Amount per tablet
(mg) Subject Compound 2 6 Hydroxypropyl methylcellulose, USP 6
Silicon dioxide, colloidal, NF 30 Pregelatinized starch, NF 50
Magnesium stearate, USP 4 Total = 96 mg
[0199] For treatment of benign prostatic hypertrophy. Take one
tablet per day.
[0200] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example O
Oral Tablet Composition
[0201]
15EXAMPLE O Oral Tablet Composition Ingredient Amount per caplet
(mg) Subject Compound 1 6 Hydroxypropyl methylcellulose, USP 6
Magnesium stearate, USP 2 Povidone K-30, USP 10 Talc, USP 12
Microcrystalline cellulose, NF 44 Total = 80 mg
[0202] For the use in the treatment of alcoholism or opiate
addiction. Adults 12 and over take two caplets every twelve
hours.
[0203] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example P
Oral Tablet Composition
[0204]
16EXAMPLE P Oral Tablet Composition Ingredient Amount per tablet
(mg) Subject Compound 1 6 Hydroxypropyl methylcellulose, USP 12
Magnesium stearate, USP 2 Povidone K-30, USP 10 Talc, USP 12
Microcrystalline cellulose, NF 44 Total = 86 mg
[0205] For the treatment of ulcer and hyperacidity. Take two
tablets as appropriate.
[0206] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example Q
Oral Tablet Composition
[0207]
17EXAMPLE Q Oral Tablet Composition Amount per tablet (mg)
Ingredient Amount Component Subject Compound 2 10 mg/ml carrier
Carrier: Sodium citrate buffer with (percent by weight of carrier):
Lecithin 0.48% Carboxymethylcellulose 0.53 Povidone 0.50 Methyl
paraben 0.11 Propyl paraben 0.011
[0208] For the reduction of cardiac reperfusion injury.
[0209] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example R
Oral Liquid Composition
[0210]
18EXAMPLE R Oral Liquid Composition Ingredient Amount/fl oz Dose
(mg) Acetaminophen, USP 1000 Doxylamine succinate, USP 12.5
Dextromethorphan hydrobromide, USP 30 Subject Compound 2 6 Dow
XYS-40010.00 resin 3 High fructose corn syrup 16000 Polyethylene
glycol, NF 3000 Propylene glycol, USP 3000 Alcohol, USP 2500 Sodium
citrate dihydrate, USP 150 Citric acid, anhydrous, USP 50 Saccharin
sodium, USP 20 Flavor 3.5 Purified water, USP 3500 Total = 29275
mg/fl oz
[0211] For the relief of minor aches, pains, headache, muscular
aches, sore throat pain, and fever associated with a cold or flu.
Relieves nasal congestion, cough due to minor throat and bronchial
irritations, runny nose, and sneezing associated with the common
cold. Adults 12 and over take one fluid ounce every six hours.
[0212] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example S
Oral Liquid Composition
[0213]
19EXAMPLE S Oral Liquid Composition Ingredient Amount/fl oz Dose
(mg) Naproxen sodium anhydrous, USP 220 Doxylamine succinate, USP
12.5 Dextromethorphan hydrobromide, USP 30 Subject Compound 1 6 Dow
XYS-40010.00 resin 3 High fructose corn syrup 16000 Polyethylene
glycol, NF 3000 Propylene glycol, USP 3000 Alcohol, USP 2500 Sodium
citrate dihydrate, USP 150 Citric acid, anhydrous, USP 50 Saccharin
sodium, USP 20 Flavor 3.5 Purified water, USP 3800 Total = 28795
mg/fl oz
[0214] For the relief of minor aches, pains, headache, muscular
aches, sore throat pain, and fever associated with a cold or flu.
Relieves nasal congestion, cough due to minor throat and bronchial
irritations, runny nose, and sneezing associated with the common
cold. Adults 12 and over take one fluid ounce every six hours.
[0215] Other compounds having a structure according to Formula I
are used with substantially similar results.
Composition Example T
[0216] A composition for parenteral administration, according to
this invention, is made comprising:
20 Component Amount Subject Compound I 10 mg/ml carrier Carrier:
Sodium citrate buffer with (percent by weight of carrier): Lecithin
0.48% Carboxymethylcellulose 0.53 Povidone 0.50 Methyl paraben 0.11
Propyl paraben 0.011
[0217] The above ingredients are mixed, forming a solution.
Approximately 2.0 ml of the solution is administered,
intravenously, to a human subject suffering from septic or
cardiogenic shock. The symptoms subside.
[0218] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example U
Oral Tablet Composition
[0219]
21EXAMPLE U Oral Tablet Composition Ingredient Amount per tablet
(mg) Subject Compound 2 10 Hydroxypropyl methylcellulose, USP 12
Magnesium stearate, USP 2 Povidone K-30, USP 10 Talc, USP 12
Microcrystalline cellulose, NF 44 Total = 90 mg
[0220] For the treatment of cardiac arrhythmia. Take as
prescribed.
[0221] Other compounds having a structure according to Formula I
are used with substantially similar results.
Example V
Oral Tablet Composition
[0222]
22 Ingredient Amount per tablet (mg) Subject Compound 1 4
Microcrystalline cellulose, NF 130 Starch 1500, NF 100 Magnesium
stearate, USP 2 Total = 236 mg
[0223] For the treatment of congestive heart failure. Take as
prescribed.
[0224] Other compounds having a structure according to Formula I
are used with substantially similar results.
[0225] Modification of the preceding embodiments is within the
scope of the skilled artisan in formulation, given the guidance of
the specification in light of the state of the art.
[0226] Other examples of combination actives are contemplated.
Examples of medicaments which can be combined with the primary
active are included in U.S. Pat. No. 4,552,899 to Sunshine, et al.,
hereby incorporated by reference. All other references referred to
throughout this specification are hereby incorporated by
reference.
[0227] While particular embodiments of this invention have been
described, it will be obvious to those skilled in the art that
various changes and modifications of this invention can be made
without departing from the spirit and scope of the invention. It is
intended to cover, in the appended claims, all such modifications
that are within the scope of this invention.
* * * * *